|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases chemical synthesis |
ISO |
CYP2C8 protein results in increased chemical synthesis of 6-hydroxytaxol |
CTD |
PMID:12401345 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
|
G |
Akt1s1 |
AKT1 substrate 1 |
decreases expression |
ISO |
cabazitaxel results in decreased expression of AKT1S1 protein |
CTD |
PMID:32525019 |
|
NCBI chr 1:100,845,443...100,851,961
Ensembl chr 1:100,845,563...100,851,960
|
|
G |
Foxo3 |
forkhead box O3 |
affects expression |
ISO |
cabazitaxel affects the expression of FOXO3 protein |
CTD |
PMID:32525019 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO |
epothilone A results in increased expression of CASP3 mRNA [epothilone A co-treated with Metformin] results in increased expression of CASP3 mRNA; Sodium Salicylate promotes the reaction [[epothilone A co-treated with Metformin] results in increased expression of CASP3 mRNA]; triciribine promotes the reaction [[epothilone A co-treated with Metformin] results in increased expression of CASP3 mRNA] |
CTD |
PMID:29117515 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
[epothilone A co-treated with Metformin] results in increased expression of H2AX mRNA epothilone A results in increased expression of H2AX mRNA |
CTD |
PMID:29117515 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases expression |
ISO |
[epothilone A co-treated with Metformin] results in increased expression of PARP1 mRNA; Sodium Salicylate inhibits the reaction [epothilone A results in increased expression of PARP1 mRNA]; triciribine inhibits the reaction [epothilone A results in increased expression of PARP1 mRNA]; triciribine promotes the reaction [[epothilone A co-treated with Metformin] results in increased expression of PARP1 mRNA] |
CTD |
PMID:29117515 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
decreases expression multiple interactions |
EXP |
epothilone B results in decreased expression of CALCA protein epothilone B affects the reaction [[Capsaicin co-treated with NGF protein] results in increased secretion of CALCA protein]; epothilone B inhibits the reaction [Potassium results in increased secretion of CALCA protein]; epothilone B promotes the reaction [[Potassium co-treated with NGF protein] results in increased secretion of CALCA protein] |
CTD |
PMID:26883566 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
epothilone B affects the reaction [[Capsaicin co-treated with NGF protein] results in increased secretion of CALCA protein]; epothilone B promotes the reaction [[Potassium co-treated with NGF protein] results in increased secretion of CALCA protein] |
CTD |
PMID:26883566 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
|
G |
Abca5 |
ATP binding cassette subfamily A member 5 |
increases expression |
ISO |
Paclitaxel results in increased expression of ABCA5 mRNA |
CTD |
PMID:20737486 |
|
NCBI chr10:98,573,226...98,645,028
Ensembl chr10:98,576,039...98,644,938
|
|
G |
Abca7 |
ATP binding cassette subfamily A member 7 |
increases expression |
ISO |
Paclitaxel results in increased expression of ABCA7 mRNA |
CTD |
PMID:20737486 |
|
NCBI chr 7:12,742,433...12,762,423
Ensembl chr 7:12,742,433...12,762,341
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
Paclitaxel results in decreased activity of ABCB11 protein |
CTD |
PMID:20829430 PMID:23956101 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects metabolic processing multiple interactions increases expression affects uptake increases export decreases response to substance increases activity increases transport decreases uptake increases response to substance affects response to substance |
ISO |
ABCB1 gene polymorphism affects the metabolism of Paclitaxel [Curcumin co-treated with Calcitriol] inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; Calcitriol promotes the reaction [Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein] ABCB1A protein affects the uptake of Paclitaxel ABCB1 protein results in increased export of Paclitaxel ABCB1 mRNA results in decreased susceptibility to Paclitaxel; ABCB1 protein results in decreased susceptibility to Paclitaxel 6-OH-BDE-47 inhibits the reaction [ABCB1 protein results in increased export of Paclitaxel]; [Calcitriol co-treated with Curcumin] inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; [Calcitriol co-treated with Paclitaxel] results in increased expression of ABCB1 mRNA; [Calcitriol co-treated with Paclitaxel] results in increased expression of ABCB1 protein; [Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel]] which results in decreased susceptibility to Paclitaxel; [Curcumin co-treated with Calcitriol] inhibits the reaction [Paclitaxel results in increased expression of ABCB1 mRNA]; [Curcumin co-treated with Paclitaxel] results in increased expression of ABCB1 protein; [CXCL8 results in increased expression of ABCB1 mRNA] which results in decreased susceptibility to Paclitaxel; [CXCL8 results in increased expression of ABCB1 protein] which results in decreased susceptibility to Paclitaxel; [Cyclosporine results in decreased activity of ABCB1 protein] which results in increased susceptibility to Paclitaxel; [Paclitaxel co-treated with IL6 protein] results in increased expression of ABCB1 protein; [Paclitaxel results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Cisplatin; [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Doxorubicin; [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Fluorouracil; [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Vincristine; [valspodar results in decreased activity of ABCB1 protein] which results in increased susceptibility to Paclitaxel; [Verapamil results in decreased activity of ABCB1 protein] which results in increased susceptibility to Paclitaxel; ABCB1 protein affects the reaction [acetochlor results in increased susceptibility to Paclitaxel]; ABCB1 protein affects the reaction [alachlor results in increased susceptibility to Paclitaxel]; ABCB1 protein affects the reaction [metolachlor results in increased susceptibility to Paclitaxel]; ABCB1 protein results in increased export of and affects the susceptibility to Paclitaxel; Calcitriol inhibits the reaction [[Curcumin co-treated with Paclitaxel] results in increased expression of ABCB1 protein]; Calcitriol inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel]; CEP 33779 inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; cinchonine analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; cinchonine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Curcumin analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Curcumin inhibits the reaction [[Calcitriol co-treated with Paclitaxel] results in increased expression of ABCB1 mRNA]; Curcumin inhibits the reaction [[Calcitriol co-treated with Paclitaxel] results in increased expression of ABCB1 protein]; Curcumin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 mRNA]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCB1 protein]; Ketoconazole inhibits the reaction [Paclitaxel results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Paclitaxel results in increased expression of and results in increased activity of ABCB1 protein]; Paclitaxel results in increased expression of and binds to and results in increased activity of ABCB1 protein; propiconazole inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Quinidine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Verapamil inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel] Paclitaxel results in increased expression of ABCB1 mRNA; Paclitaxel results in increased expression of ABCB1 protein Paclitaxel results in increased activity of ABCB1 protein ABCB1 protein results in decreased uptake of Paclitaxel ABCB1 mRNA results in increased susceptibility to Paclitaxel ABCB1 gene SNP affects the susceptibility to Paclitaxel |
CTD |
PMID:10562306 PMID:10617675 PMID:12708479 PMID:14512701 PMID:15239142 PMID:15252144 PMID:15650019 PMID:15901749 PMID:15990222 PMID:16322897 PMID:16819505 PMID:16831368 PMID:16950614 PMID:17284363 PMID:17697605 PMID:18433974 PMID:18673531 PMID:20041327 PMID:20196146 PMID:21742513 PMID:21833476 PMID:22233293 PMID:22792399 PMID:23707768 PMID:25058526 PMID:25268938 PMID:26689174 PMID:27664577 PMID:28031414 PMID:29341321 PMID:29625142 PMID:31628941 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects uptake |
ISO |
ABCB1B protein affects the uptake of Paclitaxel |
CTD |
PMID:10562306 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases response to substance |
ISO |
ABCB4 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:17697605 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of ABCB6 mRNA |
CTD |
PMID:20737486 |
|
NCBI chr 9:82,373,950...82,382,228
Ensembl chr 9:82,373,946...82,382,272
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases response to substance multiple interactions |
ISO |
ABCC1 results in decreased susceptibility to Paclitaxel [Paclitaxel co-treated with IL6 protein] results in increased expression of ABCC1 protein; HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCC1 protein] |
CTD |
PMID:15548710 PMID:29341321 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc10 |
ATP binding cassette subfamily C member 10 |
multiple interactions increases expression decreases response to substance |
ISO |
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased susceptibility to Paclitaxel]; ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel; Imatinib Mesylate inhibits the reaction [ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel]; Imatinib Mesylate inhibits the reaction [ABCC10 protein results in decreased susceptibility to Paclitaxel] Paclitaxel results in increased expression of ABCC10 mRNA |
CTD |
PMID:19841739 PMID:20737486 |
|
NCBI chr 9:17,041,351...17,061,263
Ensembl chr 9:17,041,389...17,063,780
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases response to substance increases expression affects expression increases export affects transport multiple interactions affects response to substance |
ISO |
ABCC2 protein results in decreased susceptibility to Paclitaxel Paclitaxel results in increased expression of ABCC2 mRNA; Paclitaxel results in increased expression of ABCC2 protein Paclitaxel affects the expression of ABCC2 mRNA ABCC2 protein results in increased export of Paclitaxel ABCC2 protein affects the transport of Paclitaxel montelukast inhibits the reaction [ABCC2 protein results in increased export of Paclitaxel]; Probenecid promotes the reaction [ABCC2 protein affects the transport of Paclitaxel]; Probenecid promotes the reaction [ABCC2 protein results in decreased susceptibility to Paclitaxel]; verlukast inhibits the reaction [ABCC2 protein results in increased export of Paclitaxel] ABCC2 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:15645438 PMID:15849751 PMID:19952419 PMID:20737486 PMID:28242239 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
Paclitaxel results in increased expression of ABCC3 mRNA; Paclitaxel results in increased expression of ABCC3 protein |
CTD |
PMID:20737486 PMID:29625142 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
EXP |
Paclitaxel results in increased expression of ABCC4 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
increases expression |
ISO |
Paclitaxel results in increased expression of ABCC5 mRNA |
CTD |
PMID:20737486 |
|
NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of ABCG2 mRNA; [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Paclitaxel; [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Cisplatin; [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Doxorubicin; [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Fluorouracil; [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Vincristine Paclitaxel results in decreased expression of ABCG2 mRNA; Paclitaxel results in decreased expression of ABCG2 protein |
CTD |
PMID:20705681 PMID:21712253 PMID:21833476 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of ABL1 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
decreases expression |
ISO |
Paclitaxel results in decreased expression of ACADL protein |
CTD |
PMID:15907983 |
|
NCBI chr 9:73,833,368...73,871,857
Ensembl chr 9:73,833,388...73,871,888
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
decreases response to substance |
ISO |
ACKR3 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
|
|
G |
Acot8 |
acyl-CoA thioesterase 8 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of ACOT8 protein |
CTD |
PMID:30667213 |
|
NCBI chr 3:161,260,837...161,272,495
Ensembl chr 3:161,259,735...161,272,460
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression |
ISO |
Paclitaxel results in increased expression of ACTA2 protein |
CTD |
PMID:31170432 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Adamts13 |
ADAM metallopeptidase with thrombospondin type 1 motif, 13 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of ADAMTS13 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 3:5,519,921...5,558,390
Ensembl chr 3:5,519,990...5,558,166
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] affects the expression of ADAMTS4 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr13:89,622,996...89,632,485
Ensembl chr13:89,622,632...89,634,419
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of ADAMTS5 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr11:25,411,174...25,456,639
Ensembl chr11:25,410,975...25,456,836
|
|
G |
Adamts7 |
ADAM metallopeptidase with thrombospondin type 1 motif, 7 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of ADAMTS7 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 8:97,535,777...97,575,661
Ensembl chr 8:97,535,777...97,575,655
|
|
G |
Adamtsl4 |
ADAMTS-like 4 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of ADAMTSL4 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 2:197,803,572...197,815,058
Ensembl chr 2:197,803,584...197,814,808
|
|
G |
Adcy6 |
adenylate cyclase 6 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of ADCY6 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 7:140,270,678...140,291,722
Ensembl chr 7:140,270,692...140,291,620
|
|
G |
Add3 |
adducin 3 |
affects response to substance |
ISO |
ADD3 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 1:273,854,195...273,961,982
Ensembl chr 1:273,854,248...273,961,982
|
|
G |
Adss |
adenylosuccinate synthase |
decreases expression |
ISO |
Paclitaxel results in decreased expression of ADSS2 protein |
CTD |
PMID:15907983 |
|
NCBI chr13:95,913,426...95,943,761
Ensembl chr13:95,913,426...95,943,761
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of AGT mRNA |
CTD |
PMID:20705681 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions increases expression |
ISO |
[Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased expression of AIFM1 protein; [Doxorubicin co-treated with Paclitaxel] results in increased expression of AIFM1 protein; [Tretinoin co-treated with Paclitaxel] affects the localization of AIFM1 protein; [Tretinoin co-treated with Paclitaxel] results in increased expression of AIFM1 protein Paclitaxel results in increased expression of AIFM1 mRNA |
CTD |
PMID:16168113 PMID:17701358 PMID:18058816 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
increases response to substance |
ISO |
AKR1B1 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
increases expression |
EXP |
Paclitaxel analog results in increased expression of AKR1B7 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 4:61,850,256...61,879,733
Ensembl chr 4:61,850,348...61,862,526
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases response to substance |
ISO |
AKR1C2 mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation decreases response to substance decreases phosphorylation increases activity affects response to substance |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein]; [Paclitaxel co-treated with Metformin] results in decreased expression of AKT1 mRNA; [PDK1 protein binds to AKT1 protein] results in decreased susceptibility to [Paclitaxel co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]; [PDK1 protein binds to AKT1 protein] which results in decreased susceptibility to Paclitaxel; [pifithrin co-treated with Paclitaxel] results in decreased phosphorylation of AKT1 protein; AKT1 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; AKT1 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; U 0126 inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein] Paclitaxel results in increased phosphorylation of AKT1 protein AKT1 protein results in decreased susceptibility to Paclitaxel Paclitaxel results in decreased phosphorylation of AKT1 protein AKT1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:10075725 PMID:16211241 PMID:16782806 PMID:17404021 PMID:18071906 PMID:18516295 PMID:19426673 PMID:20361045 PMID:23956100 PMID:27769712 PMID:29309887 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
affects response to substance increases phosphorylation |
ISO |
AKT2 protein affects the susceptibility to Paclitaxel Paclitaxel results in increased phosphorylation of AKT2 protein |
CTD |
PMID:18071906 |
|
NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
affects response to substance |
ISO |
AKT3 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:18071906 |
|
NCBI chr13:95,076,308...95,348,913
Ensembl chr13:95,081,390...95,348,913
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression multiple interactions |
ISO |
Paclitaxel results in decreased expression of ALDH1A1 protein [Calcitriol co-treated with Curcumin] inhibits the reaction [Paclitaxel results in decreased expression of ALDH1A1 protein] Paclitaxel results in decreased expression of ALDH1A1 mRNA; Paclitaxel results in decreased expression of ALDH1A1 protein [Calcitriol co-treated with Curcumin] promotes the reaction [Paclitaxel results in decreased expression of ALDH1A1 mRNA]; [Calcitriol co-treated with Paclitaxel] promotes the reaction [Curcumin results in decreased expression of ALDH1A1 mRNA]; [Curcumin co-treated with Calcitriol] inhibits the reaction [Paclitaxel results in decreased expression of ALDH1A1 protein]; [Curcumin co-treated with Paclitaxel] promotes the reaction [Calcitriol results in decreased expression of ALDH1A1 mRNA]; Curcumin promotes the reaction [Paclitaxel results in decreased expression of ALDH1A1 protein]; Paclitaxel promotes the reaction [Calcitriol results in decreased expression of ALDH1A1 mRNA]; Paclitaxel promotes the reaction [Curcumin results in decreased expression of ALDH1A1 mRNA] |
CTD |
PMID:31628941 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
increases expression |
ISO |
Paclitaxel results in increased expression of ALDH9A1 protein |
CTD |
PMID:15907983 |
|
NCBI chr13:85,580,828...85,597,497
Ensembl chr13:85,580,828...85,597,493
|
|
G |
Alg8 |
ALG8, alpha-1,3-glucosyltransferase |
affects response to substance |
ISO |
ALG8 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 1:162,342,061...162,362,139
Ensembl chr 1:162,342,051...162,362,141
|
|
G |
Amacr |
alpha-methylacyl-CoA racemase |
increases expression |
EXP |
Paclitaxel results in increased expression of AMACR mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 2:60,949,276...60,961,342
Ensembl chr 2:60,949,256...60,961,326
|
|
G |
Amfr |
autocrine motility factor receptor |
multiple interactions |
ISO |
AMFR mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr19:11,473,538...11,509,500
Ensembl chr19:11,473,541...11,508,102
|
|
G |
Ang |
angiogenin |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of ANG mRNA |
CTD |
PMID:20705681 |
|
NCBI chr15:28,022,926...28,028,636
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of ANGPT1 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
|
|
G |
Anp32a |
acidic nuclear phosphoprotein 32 family member A |
affects response to substance |
ISO |
ANP32A protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 8:67,295,578...67,333,075
Ensembl chr 8:67,295,727...67,333,247
|
|
G |
Anxa1 |
annexin A1 |
increases response to substance |
ISO |
ANXA1 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
Anxa4 |
annexin A4 |
decreases response to substance |
ISO |
ANXA4 results in decreased susceptibility to Paclitaxel |
CTD |
PMID:21636539 |
|
NCBI chr 4:118,538,775...118,595,591
Ensembl chr 4:118,538,777...118,595,580
|
|
G |
Anxa8 |
annexin A8 |
increases response to substance |
ISO |
ANXA8 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr16:10,417,174...10,432,388
Ensembl chr16:10,417,185...10,432,393
|
|
G |
Aox1 |
aldehyde oxidase 1 |
affects response to substance |
ISO |
AOX1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression multiple interactions |
ISO |
Paclitaxel results in increased expression of APAF1 protein [Paclitaxel co-treated with Metformin] results in increased expression of APAF1 mRNA APAF1 protein affects the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein] |
CTD |
PMID:14749477 PMID:17652622 PMID:29309887 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Apbb1ip |
amyloid beta precursor protein binding family B member 1 interacting protein |
increases expression |
EXP |
Paclitaxel results in increased expression of APBB1IP mRNA |
CTD |
PMID:18754875 |
|
NCBI chr17:90,098,953...90,149,192
Ensembl chr17:90,099,025...90,149,894
|
|
G |
Aplp2 |
amyloid beta precursor like protein 2 |
affects response to substance |
ISO |
APLP2 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 8:32,298,526...32,328,821
Ensembl chr 8:32,298,532...32,328,839
|
|
G |
Apod |
apolipoprotein D |
increases expression |
ISO |
Paclitaxel results in increased expression of APOD mRNA |
CTD |
PMID:19682730 |
|
NCBI chr11:72,705,204...72,726,263
Ensembl chr11:72,705,129...72,726,301
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases localization |
ISO |
Paclitaxel inhibits the reaction [Dihydrotestosterone results in increased localization of AR protein] Paclitaxel results in decreased localization of AR protein |
CTD |
PMID:20807808 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
Paclitaxel results in increased expression of AREG protein |
CTD |
PMID:20726858 |
|
NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
|
|
G |
Arf3 |
ADP-ribosylation factor 3 |
affects response to substance |
ISO |
ARF3 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 7:140,412,463...140,438,751
Ensembl chr 7:140,398,199...140,437,467
|
|
G |
Arhgap24 |
Rho GTPase activating protein 24 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of ARHGAP24 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr14:8,383,211...8,600,526
Ensembl chr14:8,383,214...8,600,512
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
multiple interactions affects response to substance |
ISO |
ARHGDIA mRNA affects the reaction [Paclitaxel results in increased activity of CASP3 protein] ARHGDIA mRNA affects the susceptibility to Paclitaxel |
CTD |
PMID:17264767 |
|
NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
|
|
G |
Arr3 |
arrestin 3 |
decreases response to substance |
ISO |
ARR3 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr X:70,438,590...70,452,140
Ensembl chr X:70,438,617...70,452,067
|
|
G |
Aspm |
assembly factor for spindle microtubules |
increases expression |
ISO |
Paclitaxel results in increased expression of ASPM mRNA |
CTD |
PMID:17374387 |
|
NCBI chr13:56,546,021...56,591,793
Ensembl chr13:56,546,021...56,591,793
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions increases expression |
EXP |
Minocycline inhibits the reaction [Paclitaxel results in increased expression of ATF3 protein] |
CTD |
PMID:16854522 PMID:17005179 PMID:17686523 PMID:18754875 PMID:21050491 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atf5 |
activating transcription factor 5 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of ATF5 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
increases expression |
EXP |
Paclitaxel results in increased expression of ATP2A2 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
affects response to substance |
ISO |
ATP6V1A protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr11:61,531,386...61,584,634
Ensembl chr11:61,531,416...61,584,634
|
|
G |
Atp7a |
ATPase copper transporting alpha |
decreases response to substance increases expression |
ISO |
ATP7A protein results in decreased susceptibility to Paclitaxel Paclitaxel results in increased expression of ATP7A mRNA |
CTD |
PMID:17510416 PMID:20737486 |
|
NCBI chr X:77,076,085...77,193,644
Ensembl chr X:77,076,106...77,193,644
|
|
G |
Atr |
ATR serine/threonine kinase |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of ATR mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947
|
|
G |
Aurka |
aurora kinase A |
increases expression |
ISO |
Paclitaxel results in increased expression of AURKA mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
|
|
G |
Aven |
apoptosis and caspase activation inhibitor |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of AVEN mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 3:103,980,612...104,117,193
Ensembl chr 3:104,042,168...104,117,192
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases response to substance |
ISO |
AXL protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression multiple interactions |
ISO |
Paclitaxel results in increased expression of BAD mRNA; Paclitaxel results in increased expression of BAD protein [PD168393 co-treated with Paclitaxel] results in increased expression of BAD protein |
CTD |
PMID:10822281 PMID:16413505 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bag1 |
BAG cochaperone 1 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of BAG1 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 5:57,254,421...57,267,002
Ensembl chr 5:57,254,421...57,267,002
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases response to substance increases expression multiple interactions affects expression |
ISO |
BAK1 protein results in increased susceptibility to Paclitaxel Paclitaxel results in increased expression of BAK1 mRNA; Paclitaxel results in increased expression of BAK1 protein [BAK1 protein mutant form co-treated with BAX protein mutant form] inhibits the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein] Paclitaxel affects the expression of BAK1 mRNA; Paclitaxel affects the expression of BAK1 protein |
CTD |
PMID:10822281 PMID:17652622 PMID:17688235 PMID:24126434 |
|
NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression affects response to substance |
ISO |
[Doxorubicin co-treated with Paclitaxel] results in increased expression of BAX protein; [esculetin co-treated with Paclitaxel] results in increased expression of BAX protein; [fisetin co-treated with Paclitaxel] results in increased expression of BAX mRNA; [Paclitaxel results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein]; Curcumin promotes the reaction [Paclitaxel promotes the reaction [Calcitriol results in increased expression of BAX protein]]; Curcumin promotes the reaction [Paclitaxel results in increased expression of BAX protein]; Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of BAX protein]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in increased expression of BAX protein]]; IL6 protein inhibits the reaction [Paclitaxel results in increased expression of BAX protein]; Paclitaxel promotes the reaction [Calcitriol results in increased expression of BAX protein]; Paclitaxel promotes the reaction [Curcumin results in increased expression of BAX protein] Paclitaxel results in increased expression of BAX mRNA BAX protein affects the susceptibility to Paclitaxel [BAK1 protein mutant form co-treated with BAX protein mutant form] inhibits the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein] [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of BAX mRNA; Paclitaxel results in increased expression of BAX mRNA; Paclitaxel results in increased expression of BAX protein |
CTD |
PMID:9041188 PMID:10516758 PMID:10822281 PMID:11726273 PMID:12632493 PMID:16051289 PMID:16168113 PMID:16513327 PMID:17449502 PMID:17652622 PMID:23956100 PMID:26884726 PMID:29341321 PMID:31628941 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases response to substance increases expression |
ISO |
BBC3 protein results in increased susceptibility to Paclitaxel Paclitaxel results in increased expression of BBC3 mRNA; Paclitaxel results in increased expression of BBC3 protein |
CTD |
PMID:16481741 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bbs4 |
Bardet-Biedl syndrome 4 |
multiple interactions |
ISO |
BBS4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 8:64,115,005...64,154,432
Ensembl chr 8:64,121,392...64,154,396
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects response to substance increases phosphorylation increases expression decreases expression increases cleavage decreases degradation affects localization decreases activity multiple interactions increases response to substance decreases response to substance |
ISO |
BCL2 protein affects the susceptibility to Paclitaxel Paclitaxel results in increased phosphorylation of BCL2 protein Paclitaxel results in increased expression of BCL2 mRNA Paclitaxel results in decreased expression of BCL2 mRNA; Paclitaxel results in decreased expression of BCL2 protein Paclitaxel results in increased cleavage of BCL2 protein Paclitaxel results in decreased degradation of BCL2 protein Paclitaxel affects the localization of BCL2 protein Paclitaxel results in decreased activity of BCL2 protein 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]; [Curcumin co-treated with Calcitriol] promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]; [CXCL8 results in increased expression of BCL2 mRNA] which results in decreased susceptibility to Paclitaxel; [CXCL8 results in increased expression of BCL2 protein] which results in decreased susceptibility to Paclitaxel; [fisetin co-treated with Paclitaxel] results in increased expression of BCL2 mRNA; [Paclitaxel co-treated with Metformin] results in decreased expression of BCL2 mRNA; [Paclitaxel co-treated with Sorafenib] results in decreased expression of BCL2 protein; [Paclitaxel results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein]; [Paclitaxel results in increased phosphorylation of BCL2 protein] which results in increased susceptibility to Cisplatin; [pifithrin co-treated with Paclitaxel] results in increased phosphorylation of BCL2 protein; [Tretinoin co-treated with Paclitaxel] results in decreased expression of BCL2 protein; [Tretinoin co-treated with Paclitaxel] results in increased phosphorylation of BCL2 protein; aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Calcitriol promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2 protein]; Curcumin promotes the reaction [Calcitriol promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]]; Curcumin promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Cyclosporine promotes the reaction [Paclitaxel results in increased phosphorylation of and results in decreased activity of BCL2 protein]; Dactinomycin inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Doxorubicin promotes the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Genistein inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in decreased expression of BCL2 protein]]; IL6 protein inhibits the reaction [Paclitaxel results in decreased expression of BCL2 protein]; MAP3K1 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Paclitaxel results in decreased expression of and affects the phosphorylation of BCL2 protein; Paclitaxel results in increased phosphorylation of and results in decreased activity of BCL2 protein; Quercetin inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Resveratrol inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Staurosporine inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; TYMP inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] BCL2 protein mutant form results in increased susceptibility to Paclitaxel BCL2 mRNA results in decreased susceptibility to Paclitaxel; BCL2 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:7654318 PMID:10502406 PMID:10822281 PMID:10861090 PMID:10881025 PMID:11160861 PMID:11597122 PMID:11726273 PMID:11774260 PMID:12086014 PMID:12126962 PMID:12510025 PMID:12632493 PMID:12709826 PMID:14991574 PMID:15907805 PMID:15907983 PMID:16168113 PMID:16243823 PMID:16275990 PMID:16322897 PMID:16513327 PMID:16580691 PMID:17701358 PMID:18098270 PMID:18516295 PMID:18521433 PMID:19664330 PMID:19815708 PMID:20610805 PMID:21742513 PMID:26884726 PMID:29309887 PMID:29341321 PMID:31628941 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases response to substance increases phosphorylation increases expression decreases expression multiple interactions |
ISO |
BCL2L1 protein results in decreased susceptibility to Paclitaxel Paclitaxel results in increased phosphorylation of BCL2L1 protein Paclitaxel results in increased expression of BCL2L1 mRNA; Paclitaxel results in increased expression of BCL2L1 protein Paclitaxel results in decreased expression of BCL2L1 mRNA; Paclitaxel results in decreased expression of BCL2L1 protein [CXCL8 results in increased expression of BCL2L1 mRNA] which results in decreased susceptibility to Paclitaxel; [CXCL8 results in increased expression of BCL2L1 protein] which results in decreased susceptibility to Paclitaxel; [esculetin co-treated with Paclitaxel] results in decreased expression of BCL2L1 protein; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2L1 protein] |
CTD |
PMID:10822281 PMID:11468182 PMID:11774260 PMID:14749477 PMID:16051289 PMID:16080463 PMID:16243823 PMID:16275990 PMID:18058816 PMID:18521433 PMID:21742513 PMID:23956100 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l11 |
BCL2 like 11 |
affects response to substance |
ISO |
BCL2L11 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:17652622 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bcl6 |
BCL6, transcription repressor |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of BCL6 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075
|
|
G |
Bcl6b |
BCL6B, transcription repressor |
increases expression |
EXP |
Paclitaxel results in increased expression of BCL6B mRNA |
CTD |
PMID:18754875 |
|
NCBI chr10:56,834,363...56,840,058
Ensembl chr10:56,834,364...56,839,437
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
EXP |
1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine inhibits the reaction [Paclitaxel results in increased expression of BDNF protein] |
CTD |
PMID:30414958 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
BECN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Bgn |
biglycan |
affects response to substance |
ISO |
BGN protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr X:157,319,042...157,331,204
Ensembl chr X:157,319,046...157,331,204
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases cleavage increases expression |
ISO |
[Tretinoin co-treated with Paclitaxel] results in increased cleavage of BID protein Paclitaxel results in increased cleavage of BID protein Paclitaxel results in increased expression of BID protein |
CTD |
PMID:14749477 PMID:18098270 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Bin1 |
bridging integrator 1 |
increases expression |
ISO |
Paclitaxel results in increased expression of BIN1 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr18:25,163,575...25,222,139
Ensembl chr18:25,163,561...25,222,135
|
|
G |
Bin3 |
bridging integrator 3 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of BIN3 protein |
CTD |
PMID:15907983 |
|
NCBI chr15:51,799,339...51,818,697
Ensembl chr15:51,779,839...51,818,699
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression affects response to substance multiple interactions |
ISO |
Paclitaxel results in decreased expression of BIRC2 protein BIRC2 protein affects the susceptibility to Paclitaxel [Tretinoin co-treated with Paclitaxel] results in decreased expression of BIRC2 protein; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BIRC2 protein] |
CTD |
PMID:14749477 PMID:16217747 PMID:16243823 PMID:17701358 PMID:18098270 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression multiple interactions |
ISO |
Paclitaxel results in decreased expression of BIRC3 protein [Tretinoin co-treated with Paclitaxel] results in decreased expression of BIRC3 protein; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BIRC3 protein] |
CTD |
PMID:14749477 PMID:16243823 PMID:17701358 PMID:18098270 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases response to substance multiple interactions increases expression decreases expression |
ISO |
BIRC5 protein results in decreased susceptibility to Paclitaxel; BIRC5 results in decreased susceptibility to Paclitaxel 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased expression of BIRC5]; [4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide co-treated with Paclitaxel] results in decreased expression of BIRC5 protein; [Tretinoin co-treated with Paclitaxel] results in decreased expression of BIRC5 protein; Paclitaxel affects the reaction [BIRC5 protein affects the susceptibility to Melphalan]; Prodigiosin inhibits the reaction [Paclitaxel results in increased expression of BIRC5 protein]; vorinostat inhibits the reaction [Paclitaxel results in increased expression of BIRC5 protein] Paclitaxel results in increased expression of BIRC5; Paclitaxel results in increased expression of BIRC5 protein Paclitaxel results in decreased expression of BIRC5 mRNA; Paclitaxel results in decreased expression of BIRC5 promoter; Paclitaxel results in decreased expression of BIRC5 protein |
CTD |
PMID:12517802 PMID:14749477 PMID:15970709 PMID:16170024 PMID:16202317 PMID:16211241 PMID:16373717 PMID:17399942 PMID:17701358 PMID:18098270 PMID:19133282 PMID:19875160 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Bmi1 |
BMI1 proto-oncogene, polycomb ring finger |
decreases expression |
ISO |
Paclitaxel results in decreased expression of BMI1 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr17:85,360,439...85,370,283
Ensembl chr17:85,364,483...85,368,208
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of BMP2 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of BMP4 mRNA |
CTD |
PMID:23956100 |
|
NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
increases response to substance |
ISO |
BMP7 mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr 3:170,879,972...170,955,820
Ensembl chr 3:170,879,973...170,955,399
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases expression |
ISO |
Paclitaxel results in decreased expression of BRCA1 mRNA |
CTD |
PMID:15607317 |
|
NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
Paclitaxel results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 1:225,035,956...225,046,137
Ensembl chr 1:225,037,737...225,046,040
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
decreases expression |
EXP |
Paclitaxel results in decreased expression of BTG2 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
multiple interactions increases expression |
ISO |
BTG3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] Paclitaxel results in increased expression of BTG3 protein |
CTD |
PMID:15907983 PMID:16896004 |
|
NCBI chr11:16,873,642...16,889,100
Ensembl chr11:16,873,646...16,889,201
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
multiple interactions affects response to substance |
ISO |
[arsenic trioxide co-treated with Paclitaxel] promotes the reaction [BUB1B protein binds to CDC20 protein]; [arsenic trioxide co-treated with Paclitaxel] results in increased expression of BUB1B protein modified form BUB1B protein affects the susceptibility to Paclitaxel |
CTD |
PMID:18691855 PMID:19781537 |
|
NCBI chr 3:110,367,949...110,420,471
Ensembl chr 3:110,367,939...110,420,458
|
|
G |
Bub3 |
BUB3 mitotic checkpoint protein |
increases expression |
ISO |
Paclitaxel results in increased expression of BUB3 protein |
CTD |
PMID:15907983 |
|
NCBI chr 1:203,526,853...203,537,459
Ensembl chr 1:203,524,426...203,557,337
|
|
G |
C1qa |
complement C1q A chain |
increases expression |
EXP |
Paclitaxel results in increased expression of C1QA mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
|
|
G |
C1qb |
complement C1q B chain |
increases expression |
EXP |
Paclitaxel results in increased expression of C1QB mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 5:155,246,444...155,251,995
Ensembl chr 5:155,246,447...155,252,003
|
|
G |
C1qc |
complement C1q C chain |
increases expression |
EXP |
Paclitaxel results in increased expression of C1QC mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 5:155,255,013...155,258,631
Ensembl chr 5:155,255,005...155,258,392
|
|
G |
C1s |
complement C1s |
increases expression |
EXP |
Paclitaxel results in increased expression of C1S mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 4:157,143,592...157,155,592
Ensembl chr 4:157,143,592...157,155,609
|
|
G |
C3 |
complement C3 |
increases expression |
EXP |
Paclitaxel results in increased expression of C3 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
|
|
G |
C4a |
complement C4A |
increases expression |
EXP |
Paclitaxel results in increased expression of C4A mRNA |
CTD |
PMID:18754875 |
|
NCBI chr20:2,651,599...2,678,183
Ensembl chr20:2,651,599...2,678,141
|
|
G |
Ca12 |
carbonic anhydrase 12 |
multiple interactions |
ISO |
CA12 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 8:72,405,770...72,461,425
Ensembl chr 8:72,405,748...72,460,240
|
|
G |
Cacna2d1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
increases expression |
ISO |
Paclitaxel results in increased expression of CACNA2D1 mRNA; Paclitaxel results in increased expression of CACNA2D1 protein |
CTD |
PMID:16687474 PMID:19336915 |
|
NCBI chr 4:15,706,974...16,130,848
Ensembl chr 4:15,710,417...16,130,848
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions decreases expression increases expression |
EXP |
Cromolyn Sodium inhibits the reaction [Paclitaxel results in increased expression of CALCA protein]; Paclitaxel inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; Paclitaxel inhibits the reaction [Potassium results in increased secretion of CALCA protein]; pemirolast inhibits the reaction [Paclitaxel results in increased expression of CALCA protein] Paclitaxel results in decreased expression of CALCA protein |
CTD |
PMID:15033348 PMID:26883566 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions increases expression |
EXP |
1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine inhibits the reaction [Paclitaxel results in increased expression of CAMK2A protein] |
CTD |
PMID:30414958 |
|
NCBI chr18:56,193,978...56,295,869
Ensembl chr18:56,193,978...56,295,869
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
affects response to substance |
ISO |
CAMK2B protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
|
|
G |
Caprin1 |
cell cycle associated protein 1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CAPRIN1 mRNA |
CTD |
PMID:18058816 |
|
NCBI chr 3:93,701,830...93,789,580
Ensembl chr 3:93,702,487...93,789,617
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in increased expression of CASP1 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp12 |
caspase 12 |
decreases expression multiple interactions increases expression |
ISO |
Paclitaxel results in decreased expression of CASP12 protein [Tretinoin co-treated with Paclitaxel] results in increased expression of CASP12 protein Paclitaxel results in increased expression of CASP12 protein |
CTD |
PMID:17701358 PMID:18098270 |
|
NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
|
|
G |
Casp14 |
caspase 14 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in increased expression of CASP14 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 7:13,938,376...13,944,286
Ensembl chr 7:13,938,302...13,945,130
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression |
ISO |
[4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide co-treated with Paclitaxel] results in increased activity of CASP3 protein; [6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine co-treated with Paclitaxel] results in increased activity of CASP3 protein; [Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased activity of CASP3 protein; [Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP3 protein; [esculetin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein; [fisetin co-treated with Paclitaxel] results in increased expression of CASP3 mRNA; [Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; [Paclitaxel co-treated with Cisplatin] results in increased activity of CASP3 protein; [PD168393 co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein; [pifithrin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; [tipifarnib co-treated with Paclitaxel] results in increased activity of CASP3 protein; [Tretinoin co-treated with Paclitaxel] results in increased activity of CASP3 protein; AKT1 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; alvocidib promotes the reaction [Paclitaxel results in increased activity of CASP3 protein]; ARHGDIA mRNA affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; CD40LG protein inhibits the reaction [Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; CXCL8 inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein]; inostamycin promotes the reaction [Paclitaxel results in increased expression of CASP3 protein modified form]; MAP2K4 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; MAP3K5 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein]; Nicotine inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein]; Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; Paclitaxel promotes the reaction [NSC 74859 results in decreased expression of CASP3 protein]; Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein; Paclitaxel results in increased cleavage of and results in increased activity of CASP3 protein; Paclitaxel results in increased expression of and results in increased activity of CASP3 protein; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein]; TYMP mutant form promotes the reaction [Paclitaxel results in increased cleavage of CASP3 protein] Paclitaxel results in increased expression of CASP3 mRNA [BAK1 protein mutant form co-treated with BAX protein mutant form] inhibits the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein]; APAF1 protein affects the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein]; CASP9 protein affects the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein]; Metoclopramide inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein]; Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein Paclitaxel results in increased expression of CASP3 mRNA; Paclitaxel results in increased expression of CASP3 protein; Paclitaxel results in increased expression of CASP3 protein modified form |
CTD |
PMID:9818034 PMID:10075725 PMID:10430095 PMID:10516758 PMID:10733772 PMID:10822281 PMID:11716366 PMID:11774260 PMID:12086014 PMID:12709826 PMID:15492279 PMID:15728126 PMID:15753396 PMID:16051289 PMID:16140185 PMID:16168113 PMID:16170024 PMID:16413505 PMID:16545138 PMID:17264767 PMID:17399942 PMID:17449502 PMID:17652622 PMID:17701358 PMID:18071906 PMID:18098270 PMID:18516295 PMID:18521433 PMID:19426673 PMID:19815708 PMID:20106947 PMID:21742513 PMID:22302033 PMID:24126434 PMID:24525192 PMID:26091902 PMID:26884726 PMID:27664577 PMID:28987329 PMID:29027213 PMID:31433962 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp4 |
caspase 4 |
increases expression multiple interactions |
ISO |
Paclitaxel results in increased expression of CASP4 mRNA [Paclitaxel co-treated with Metformin] results in increased expression of CASP4 mRNA |
CTD |
PMID:18058816 PMID:29309887 |
|
NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
|
|
G |
Casp7 |
caspase 7 |
increases activity increases cleavage multiple interactions increases expression |
ISO |
Paclitaxel results in increased activity of CASP7 protein Paclitaxel results in increased cleavage of CASP7 protein [Calcitriol co-treated with Curcumin] promotes the reaction [Paclitaxel results in increased expression of CASP7 protein]; [Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased activity of CASP7 protein; [Resveratrol co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP7 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP7 protein; Calcitriol inhibits the reaction [Curcumin inhibits the reaction [Paclitaxel results in increased expression of CASP7 protein]]; Calcitriol inhibits the reaction [Paclitaxel results in increased expression of CASP7 protein]; Curcumin inhibits the reaction [Calcitriol inhibits the reaction [Paclitaxel results in increased expression of CASP7 protein]]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of CASP7 protein]; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP7 protein] Paclitaxel results in increased expression of CASP7 mRNA; Paclitaxel results in increased expression of CASP7 protein |
CTD |
PMID:14749477 PMID:15753396 PMID:16168113 PMID:18058816 PMID:22302033 PMID:27664577 PMID:31433962 PMID:31628941 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases expression increases cleavage increases activity |
ISO |
[Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased activity of CASP8 protein; [Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP8 protein; [esculetin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP8 protein; [Luteolin co-treated with Paclitaxel] results in increased cleavage of CASP8 protein; [Paclitaxel co-treated with Metformin] results in increased expression of CASP8 mRNA; [Resveratrol co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP8 protein; [Tretinoin co-treated with Paclitaxel] results in increased cleavage of CASP8 protein; [TYMP mutant form co-treated with Paclitaxel] results in increased cleavage of CASP8 protein; Paclitaxel promotes the reaction [NSC 74859 results in decreased expression of CASP8 protein] Paclitaxel results in increased expression of CASP8 mRNA Paclitaxel results in increased expression of CASP8 mRNA; Paclitaxel results in increased expression of CASP8 protein Paclitaxel results in increased cleavage of CASP8 protein Paclitaxel results in increased activity of CASP8 protein |
CTD |
PMID:11716366 PMID:14749477 PMID:15492279 PMID:15907983 PMID:16051289 PMID:16168113 PMID:18058816 PMID:18071906 PMID:18098270 PMID:24126434 PMID:24525192 PMID:26091902 PMID:29309887 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity increases expression affects response to substance |
ISO |
[4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide co-treated with Paclitaxel] results in increased activity of CASP9 protein; [6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine co-treated with Paclitaxel] results in increased activity of CASP9 protein; [benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP9 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]; [benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP9 protein] which results in decreased susceptibility to Paclitaxel; [Calcitriol co-treated with Paclitaxel] results in increased expression of CASP9 protein; [Curcumin co-treated with Calcitriol] promotes the reaction [Paclitaxel results in increased expression of CASP9 protein]; [Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP9 protein; [Paclitaxel co-treated with Calcitriol] promotes the reaction [Curcumin results in increased expression of CASP9 protein]; [Paclitaxel co-treated with Curcumin] promotes the reaction [Calcitriol results in increased expression of CASP9 protein]; [Resveratrol co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP9 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP9 protein; [Tretinoin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP9 protein; Calcitriol inhibits the reaction [Paclitaxel results in increased expression of CASP9 protein]; Curcumin promotes the reaction [[Calcitriol co-treated with Paclitaxel] results in increased expression of CASP9 protein]; Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP9 protein]; Paclitaxel promotes the reaction [Curcumin results in increased expression of CASP9 protein]; Paclitaxel results in increased cleavage of and results in increased activity of CASP9 protein CASP9 protein affects the reaction [Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein] Paclitaxel results in increased activity of CASP9 protein Paclitaxel results in increased expression of CASP9 mRNA; Paclitaxel results in increased expression of CASP9 protein CASP9 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:14749477 PMID:15753396 PMID:15907983 PMID:16168113 PMID:16170024 PMID:17652622 PMID:17701358 PMID:18058816 PMID:18098270 PMID:18594523 PMID:24126434 PMID:31628941 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
affects response to substance increases response to substance |
ISO |
CAT protein affects the susceptibility to Paclitaxel CAT results in increased susceptibility to Paclitaxel |
CTD |
PMID:16217747 PMID:21689642 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
increases response to substance |
ISO |
CAV1 mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
Paclitaxel results in increased expression of CCAR1 mRNA |
CTD |
PMID:18058816 |
|
NCBI chr20:32,373,443...32,416,044
Ensembl chr20:32,373,443...32,416,044
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases response to substance |
ISO |
CCL2 results in increased susceptibility to Paclitaxel |
CTD |
PMID:21187454 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases response to substance |
ISO |
CCN1 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] affects the expression of CCN2 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccnb1 |
cyclin B1 |
increases response to substance affects expression multiple interactions increases expression |
ISO |
CCNB1 protein results in increased susceptibility to Paclitaxel Paclitaxel affects the expression of CCNB1 protein 4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline inhibits the reaction [Paclitaxel results in increased expression of CCNB1 protein]; [Paclitaxel co-treated with Metformin] results in decreased expression of CCNB1 mRNA; [pifithrin co-treated with Paclitaxel] results in increased expression of CCNB1 protein; alvocidib inhibits the reaction [Paclitaxel results in increased expression of CCNB1 protein]; CDK7 protein affects the reaction [Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein]]; Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein]; Paclitaxel results in increased expression of and results in increased activity of CCNB1 protein |
CTD |
PMID:10430095 PMID:14646529 PMID:16356831 PMID:16849574 PMID:18516295 PMID:24748653 PMID:27378817 PMID:27769712 PMID:29309887 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnb2 |
cyclin B2 |
affects response to substance multiple interactions |
ISO |
CCNB2 protein affects the susceptibility to Paclitaxel [Paclitaxel co-treated with Metformin] results in decreased expression of CCNB2 mRNA |
CTD |
PMID:16217747 PMID:29309887 |
|
NCBI chr 8:76,847,972...76,861,165
|
|
G |
Ccnc |
cyclin C |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CCNC mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 5:35,865,598...35,883,732
Ensembl chr 5:35,865,605...35,883,706
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CCND1 mRNA; Curcumin inhibits the reaction [Paclitaxel results in increased expression of CCND1 protein] Paclitaxel results in decreased expression of CCND1 mRNA |
CTD |
PMID:16243823 PMID:26091902 PMID:29309887 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CCND2 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CCNE1 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CCNE2 mRNA |
CTD |
PMID:12929121 PMID:15000894 |
|
NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
|
|
G |
Ccnf |
cyclin F |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CCNF mRNA |
CTD |
PMID:29309887 |
|
NCBI chr10:13,594,687...13,619,935
Ensembl chr10:13,594,687...13,619,935
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CCNG1 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325
|
|
G |
Ccng2 |
cyclin G2 |
increases expression multiple interactions |
ISO |
Paclitaxel results in increased expression of CCNG2 mRNA [Paclitaxel co-treated with Metformin] results in decreased expression of CCNG2 mRNA |
CTD |
PMID:12929121 PMID:29309887 |
|
NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
|
|
G |
Ccnh |
cyclin H |
increases expression |
ISO |
Paclitaxel results in increased expression of CCNH protein |
CTD |
PMID:15907983 |
|
NCBI chr 2:13,593,100...13,613,910
Ensembl chr 2:13,593,100...13,613,910
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions increases expression affects response to substance |
ISO EXP |
CD14 protein affects the reaction [Paclitaxel results in increased expression of IL12A mRNA]; CD14 protein affects the reaction [Paclitaxel results in increased expression of IL12B mRNA]; CD14 protein affects the reaction [Paclitaxel results in increased expression of PTGS2 mRNA]; CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein]; CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein]; CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK8 protein] Paclitaxel results in increased expression of CD14 mRNA CD14 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:11123339 PMID:11581577 PMID:18754875 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd163 |
CD163 molecule |
increases expression |
EXP |
Paclitaxel results in increased expression of CD163 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 4:156,752,063...156,785,467
Ensembl chr 4:156,752,082...156,785,467
|
|
G |
Cd24 |
CD24 molecule |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CD24 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr20:48,335,540...48,340,847
Ensembl chr20:48,335,540...48,340,846
|
|
G |
Cd274 |
CD274 molecule |
increases expression |
ISO |
Paclitaxel results in increased expression of CD274 protein |
CTD |
PMID:17920123 |
|
NCBI chr 1:247,519,890...247,539,659
Ensembl chr 1:247,519,939...247,537,943
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
EXP |
Paclitaxel analog results in increased expression of CD36 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cd40lg |
CD40 ligand |
multiple interactions decreases response to substance |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CD40LG mRNA; CD40LG protein inhibits the reaction [Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]] CD40LG protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16545138 PMID:29309887 |
|
NCBI chr X:159,703,703...159,714,886
Ensembl chr X:159,703,578...159,716,562
|
|
G |
Cd46 |
CD46 molecule |
increases response to substance |
ISO |
CD46 mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr13:113,786,525...113,818,741
Ensembl chr13:113,787,349...113,817,995
|
|
G |
Cd47 |
Cd47 molecule |
decreases response to substance |
ISO |
CD47 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr11:53,511,485...53,575,754
Ensembl chr11:53,514,595...53,575,175
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
EXP |
Paclitaxel results in increased expression of CD68 protein |
CTD |
PMID:16854522 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Cda |
cytidine deaminase |
affects response to substance |
ISO |
CDA protein affects the susceptibility to Paclitaxel |
CTD |
PMID:18728667 |
|
NCBI chr 5:156,703,579...156,734,541
Ensembl chr 5:156,703,579...156,734,541
|
|
G |
Cdc14b |
cell division cycle 14B |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CDC14B mRNA |
CTD |
PMID:18058816 |
|
NCBI chr17:1,709,703...1,797,732
Ensembl chr17:1,703,943...1,797,750
|
|
G |
Cdc16 |
cell division cycle 16 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CDC16 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr16:81,493,355...81,516,493
Ensembl chr16:81,493,355...81,516,493
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with Paclitaxel] promotes the reaction [BUB1B protein binds to CDC20 protein]; [Paclitaxel co-treated with Metformin] results in decreased expression of CDC20 mRNA |
CTD |
PMID:19781537 PMID:29309887 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdc25a |
cell division cycle 25A |
increases expression multiple interactions |
ISO |
Paclitaxel results in increased expression of CDC25A mRNA [Paclitaxel co-treated with Metformin] results in decreased expression of CDC25A mRNA |
CTD |
PMID:12929121 PMID:29309887 |
|
NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Paclitaxel] results in increased expression of CDC25C protein modified form; [pifithrin co-treated with Paclitaxel] results in increased phosphorylation of CDC25C protein Paclitaxel results in decreased expression of CDC25C mRNA |
CTD |
PMID:18058816 PMID:18516295 PMID:19781537 |
|
NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
|
|
G |
Cdc27 |
cell division cycle 27 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Paclitaxel] results in increased expression of CDC27 protein modified form |
CTD |
PMID:19781537 |
|
NCBI chr10:92,551,754...92,602,214
Ensembl chr10:92,554,081...92,602,082
|
|
G |
Cdc34 |
cell division cycle 34, ubiqiutin conjugating enzyme |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CDC34 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 7:12,899,957...12,905,339
Ensembl chr 7:12,899,958...12,905,339
|
|
G |
Cdc5l |
cell division cycle 5-like |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CDC5L mRNA |
CTD |
PMID:18058816 |
|
NCBI chr 9:17,949,764...17,988,514
Ensembl chr 9:17,949,764...17,988,509
|
|
G |
Cdc73 |
cell division cycle 73 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CDC73 mRNA |
CTD |
PMID:18058816 |
|
NCBI chr13:60,403,771...60,496,511
Ensembl chr13:60,403,771...60,496,511
|
|
G |
Cdca7 |
cell division cycle associated 7 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CDCA7 mRNA |
CTD |
PMID:18058816 |
|
NCBI chr 3:59,153,281...59,163,916
Ensembl chr 3:59,153,280...59,163,913
|
|
G |
Cdh11 |
cadherin 11 |
increases expression |
ISO |
Paclitaxel results in increased expression of CDH11 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr19:2,391,181...2,551,245
Ensembl chr19:2,393,059...2,551,245
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions decreases expression increases activity |
ISO |
[Arsenic Trioxide co-treated with Paclitaxel] results in increased activity of CDK1 protein; [Arsenic Trioxide co-treated with Paclitaxel] results in increased expression of CDK1 protein modified form; [Paclitaxel co-treated with Metformin] results in decreased expression of CDK1 mRNA; [pifithrin co-treated with Paclitaxel] results in decreased phosphorylation of CDK1 protein; bryostatin 1 inhibits the reaction [Paclitaxel results in increased activity of CDK1 protein] Paclitaxel results in decreased expression of CDK1 mRNA |
CTD |
PMID:10516758 PMID:18058816 PMID:18516295 PMID:19781537 PMID:29309887 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk16 |
cyclin-dependent kinase 16 |
increases expression |
EXP |
Paclitaxel analog results in increased expression of CDK16 mRNA; Paclitaxel results in increased expression of CDK16 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr X:1,707,285...1,718,821
Ensembl chr X:1,707,289...1,718,637
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions increases activity |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CDK2 mRNA; alvocidib inhibits the reaction [Paclitaxel results in increased activity of CDK2 protein]; CDK7 protein affects the reaction [Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein]]; Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein] |
CTD |
PMID:10430095 PMID:14646529 PMID:29309887 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk20 |
cyclin-dependent kinase 20 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CDK20 mRNA |
CTD |
PMID:18058816 |
|
NCBI chr17:1,935,900...1,942,867
Ensembl chr17:1,936,163...1,942,865
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CDK4 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CDK5R1 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr10:67,862,054...67,863,255
Ensembl chr10:67,862,054...67,863,255
|
|
G |
Cdk7 |
cyclin-dependent kinase 7 |
multiple interactions increases activity |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CDK7 mRNA; CDK7 protein affects the reaction [Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein]] Paclitaxel results in increased activity of CDK7 protein |
CTD |
PMID:14646529 PMID:29309887 |
|
NCBI chr 2:30,710,642...30,735,522
Ensembl chr 2:30,710,643...30,735,514
|
|
G |
Cdk8 |
cyclin-dependent kinase 8 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CDK8 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr12:10,496,273...10,561,335
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression increases expression multiple interactions |
ISO |
Paclitaxel results in decreased expression of CDKN1A mRNA Paclitaxel results in increased expression of CDKN1A mRNA; Paclitaxel results in increased expression of CDKN1A protein [Cisplatin co-treated with Paclitaxel] results in increased expression of CDKN1A mRNA; [Doxorubicin co-treated with Paclitaxel] results in increased expression of CDKN1A protein; [PD168393 co-treated with Paclitaxel] results in increased expression of CDKN1A protein; Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of CDKN1A protein]; Nicotine inhibits the reaction [Paclitaxel results in increased expression of CDKN1A protein]; pifithrin inhibits the reaction [Paclitaxel results in increased expression of CDKN1A protein] [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of CDKN1A mRNA; Paclitaxel results in increased expression of CDKN1A protein |
CTD |
PMID:9041188 PMID:9231689 PMID:12929121 PMID:16168113 PMID:16413505 PMID:16601104 PMID:18516295 PMID:20705681 PMID:24211769 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in increased expression of CDKN1B mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
affects response to substance |
ISO |
CDKN2C protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 5:129,347,731...129,352,886
Ensembl chr 5:129,347,732...129,352,886
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of CEACAM1 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 1:82,327,955...82,344,345
Ensembl chr 1:82,327,955...82,344,345
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
EXP |
Paclitaxel results in increased expression of CEBPD mRNA |
CTD |
PMID:18754875 |
|
NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
|
|
G |
Cenpf |
centromere protein F |
multiple interactions increases expression |
ISO |
Lovastatin promotes the reaction [Paclitaxel results in increased expression of CENPF protein]; Mevalonic Acid inhibits the reaction [Paclitaxel results in increased expression of CENPF protein] |
CTD |
PMID:12467231 |
|
NCBI chr13:108,132,499...108,178,609
Ensembl chr13:108,132,499...108,178,609
|
|
G |
Cenps |
centromere protein S |
increases expression |
ISO |
Paclitaxel results in increased expression of CENPS mRNA |
CTD |
PMID:18058816 |
|
NCBI chr 5:165,946,106...165,955,723
|
|
G |
Cfb |
complement factor B |
increases expression |
EXP |
Paclitaxel results in increased expression of CFB mRNA |
CTD |
PMID:18754875 |
|
NCBI chr20:4,536,206...4,542,073
Ensembl chr20:4,536,203...4,561,066 Ensembl chr20:4,536,203...4,561,066
|
|
G |
Cfd |
complement factor D |
increases expression |
EXP |
Paclitaxel results in increased expression of CFD mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 7:12,634,216...12,635,939
Ensembl chr 7:12,634,216...12,635,943
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases response to substance |
ISO |
CFLAR protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16080463 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chchd3 |
coiled-coil-helix-coiled-coil-helix domain containing 3 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CHCHD3 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 4:60,080,536...60,358,592
Ensembl chr 4:60,080,538...60,358,562
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases expression multiple interactions |
ISO |
Paclitaxel results in decreased expression of CHEK1 mRNA [Paclitaxel co-treated with Metformin] results in decreased expression of CHEK1 mRNA |
CTD |
PMID:12929121 PMID:29309887 |
|
NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of CHEK2 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Chfr |
checkpoint with forkhead and ring finger domains |
affects response to substance decreases response to substance |
ISO |
CHFR protein modified form affects the susceptibility to Paclitaxel CHFR protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:17786301 |
|
NCBI chr12:52,562,594...52,596,162
Ensembl chr12:52,562,597...52,596,076
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
increases expression |
EXP |
Paclitaxel results in increased expression of CHI3L1 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr13:51,022,844...51,030,797
Ensembl chr13:51,022,681...51,030,802
|
|
G |
Cideb |
cell death-inducing DFFA-like effector b |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CIDEB mRNA |
CTD |
PMID:12929121 |
|
NCBI chr15:34,439,844...34,444,244
Ensembl chr15:34,439,876...34,444,244
|
|
G |
Cldn3 |
claudin 3 |
decreases response to substance |
ISO |
CLDN3 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr12:21,831,341...21,832,813
Ensembl chr12:21,831,342...21,832,813
|
|
G |
Clec10a |
C-type lectin domain containing 10A |
increases expression |
EXP |
Paclitaxel results in increased expression of CLEC10A mRNA |
CTD |
PMID:18754875 |
|
NCBI chr10:56,764,927...56,769,447
Ensembl chr10:56,764,927...56,769,457
|
|
G |
Clec11a |
C-type lectin domain containing 11A |
increases expression |
ISO |
Paclitaxel results in increased expression of CLEC11A mRNA |
CTD |
PMID:19682730 |
|
NCBI chr 1:100,290,374...100,293,515
Ensembl chr 1:100,289,295...100,293,558
|
|
G |
Clpx |
caseinolytic mitochondrial matrix peptidase chaperone subunit X |
increases expression |
ISO |
Paclitaxel results in increased expression of CLPX protein |
CTD |
PMID:15907983 |
|
NCBI chr 8:70,789,137...70,843,133
Ensembl chr 8:70,789,256...70,843,123
|
|
G |
Clu |
clusterin |
decreases response to substance |
ISO |
CLU protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:15955107 PMID:16308731 |
|
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions increases expression |
EXP |
1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine inhibits the reaction [Paclitaxel results in increased expression of CNR2 protein]; [1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel; [3-(1,1-dimethyl-heptyl)-1-9-dihydroxy-benzo(c)chromen-6-one binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel; [AM 1241 binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel; iodopravadoline inhibits the reaction [[1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel]; SR 144528 inhibits the reaction [[3-(1,1-dimethyl-heptyl)-1-9-dihydroxy-benzo(c)chromen-6-one binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel]; SR 144528 inhibits the reaction [[AM 1241 binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel] |
CTD |
PMID:18664590 PMID:18846037 PMID:30414958 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Coch |
cochlin |
increases expression |
EXP |
Paclitaxel results in increased expression of COCH mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 6:72,359,702...72,373,710
Ensembl chr 6:72,359,791...72,373,695
|
|
G |
Col11a2 |
collagen type XI alpha 2 chain |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] affects the expression of COL11A2 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr20:3,829,324...3,859,022
Ensembl chr20:3,830,164...3,859,018
|
|
G |
Col15a1 |
collagen type XV alpha 1 chain |
decreases response to substance |
ISO |
COL15A1 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:25199881 |
|
NCBI chr 5:62,840,360...62,950,240
|
|
G |
Col17a1 |
collagen type XVII alpha 1 chain |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] affects the expression of COL17A1 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 1:267,416,681...267,465,049
Ensembl chr 1:267,417,459...267,463,705
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
increases expression |
ISO |
Paclitaxel results in increased expression of COL18A1 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr20:12,225,202...12,332,858
Ensembl chr20:12,225,202...12,332,858
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Paclitaxel results in increased expression of COL1A1 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases response to substance increases expression |
ISO |
COL1A2 mRNA results in increased susceptibility to Paclitaxel Paclitaxel results in increased expression of COL1A2 mRNA |
CTD |
PMID:19682730 PMID:25199881 |
|
NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
|
|
G |
Col20a1 |
collagen type XX alpha 1 chain |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of COL20A1 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 3:176,491,292...176,526,009
Ensembl chr 3:176,494,768...176,526,018
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions decreases response to substance |
ISO |
[Cisplatin co-treated with Paclitaxel] affects the expression of COL3A1 mRNA COL3A1 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:20705681 PMID:25199881 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
increases expression |
ISO |
Paclitaxel results in increased expression of COL4A1 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
|
|
G |
Col4a2 |
collagen type IV alpha 2 chain |
multiple interactions increases expression |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of COL4A2 mRNA Paclitaxel results in increased expression of COL4A2 mRNA |
CTD |
PMID:19682730 PMID:20705681 |
|
NCBI chr16:83,386,388...83,522,169
Ensembl chr16:83,387,364...83,438,561
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
decreases response to substance |
ISO |
COL5A2 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:25199881 |
|
NCBI chr 9:52,091,088...52,238,735
Ensembl chr 9:52,092,511...52,238,564
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
increases expression |
ISO |
Paclitaxel results in increased expression of COL6A1 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr20:12,657,913...12,676,370
Ensembl chr20:12,658,065...12,675,561
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
increases expression |
ISO |
Paclitaxel results in increased expression of COL6A2 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr20:12,773,472...12,801,179
Ensembl chr20:12,773,427...12,801,180
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
affects response to substance |
ISO |
COL6A3 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 9:97,926,784...98,004,643
Ensembl chr 9:97,926,787...98,004,546
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
increases response to substance |
ISO |
COL7A1 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 8:117,694,441...117,726,844
Ensembl chr 8:117,694,605...117,726,844
|
|
G |
Cope |
COPI coat complex subunit epsilon |
affects response to substance |
ISO |
COPE protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr16:20,863,141...20,873,516
Ensembl chr16:20,863,141...20,873,521
|
|
G |
Cox15 |
cytochrome c oxidase assembly homolog COX15 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of COX15 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 1:263,494,850...263,511,510
Ensembl chr 1:263,494,852...263,511,505
|
|
G |
Cox17 |
cytochrome c oxidase copper chaperone COX17 |
affects response to substance |
ISO |
COX17 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr11:64,962,663...64,968,437
Ensembl chr11:64,962,666...64,968,437
|
|
G |
Cp |
ceruloplasmin |
increases expression |
EXP |
Paclitaxel results in increased expression of CP mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CPT1A protein |
CTD |
PMID:30667213 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CPT2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 5:127,505,646...127,523,016
Ensembl chr 5:127,505,614...127,523,089
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation multiple interactions |
EXP |
Paclitaxel results in increased phosphorylation of CREB1 protein 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine inhibits the reaction [Paclitaxel results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:30414958 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Creg1 |
cellular repressor of E1A-stimulated genes 1 |
affects response to substance |
ISO |
CREG1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr13:83,972,186...83,984,675
Ensembl chr13:83,972,212...83,984,675
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions |
ISO |
[CSF3 protein co-treated with Paclitaxel] results in decreased abundance of Choline; [CSF3 protein co-treated with Paclitaxel] results in decreased abundance of Creatine; [CSF3 protein co-treated with Paclitaxel] results in decreased abundance of Inositol |
CTD |
PMID:9018096 |
|
NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of CTBP1 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr14:82,762,109...82,789,350
Ensembl chr14:82,762,190...82,789,319
|
|
G |
Ctcf |
CCCTC-binding factor |
decreases response to substance |
ISO |
CTCF mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr19:37,600,151...37,649,674
Ensembl chr19:37,600,148...37,649,673
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases response to substance decreases phosphorylation |
ISO |
CTNNB1 results in decreased susceptibility to Paclitaxel Paclitaxel results in decreased phosphorylation of CTNNB1 protein |
CTD |
PMID:22000491 PMID:23956100 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctnnd2 |
catenin delta 2 |
multiple interactions |
ISO |
CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 2:83,227,247...84,094,315
Ensembl chr 2:83,393,282...84,094,315
|
|
G |
Ctse |
cathepsin E |
increases expression |
EXP |
Paclitaxel analog results in increased expression of CTSE mRNA; Paclitaxel results in increased expression of CTSE mRNA |
CTD |
PMID:15585946 |
|
NCBI chr13:48,426,833...48,449,493
Ensembl chr13:48,426,820...48,449,490
|
|
G |
Ctsk |
cathepsin K |
increases expression |
EXP |
Paclitaxel analog results in increased expression of CTSK mRNA; Paclitaxel results in increased expression of CTSK mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
|
|
G |
Ctsl |
cathepsin L |
increases response to substance decreases response to substance |
ISO |
CTSL mRNA results in increased susceptibility to Paclitaxel CTSL protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 PMID:31370861 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Ctss |
cathepsin S |
increases expression |
EXP |
Paclitaxel results in increased expression of CTSS mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
|
|
G |
Cttn |
cortactin |
decreases expression |
ISO |
Paclitaxel results in decreased expression of CTTN protein |
CTD |
PMID:15907983 |
|
NCBI chr 1:217,602,698...217,638,196 NCBI chr 1:215,255,385...215,290,882
Ensembl chr 1:217,602,698...217,638,152 Ensembl chr 1:217,602,698...217,638,152
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Paclitaxel results in increased expression of CXCL1 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression multiple interactions |
ISO |
Paclitaxel results in increased expression of CXCL10 mRNA TLR4 protein affects the reaction [Paclitaxel results in increased expression of CXCL10 mRNA] |
CTD |
PMID:11123339 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
increases expression |
EXP |
Paclitaxel results in increased expression of CXCL14 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions decreases response to substance |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of CXCR4 mRNA CXCR4 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 PMID:20705681 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cxcr6 |
C-X-C motif chemokine receptor 6 |
decreases response to substance |
ISO |
CXCR6 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr 8:132,869,712...132,870,766
Ensembl chr 8:132,869,712...132,870,767
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions increases secretion increases expression |
ISO |
Paclitaxel affects the localization of CYCS protein [esculetin co-treated with Paclitaxel] affects the localization of CYCS protein; [PD168393 co-treated with Paclitaxel] affects the localization of CYCS protein; [resveratrol co-treated with Paclitaxel] affects the localization of CYCS protein; [tipifarnib co-treated with Paclitaxel] affects the localization of CYCS protein Paclitaxel results in increased secretion of CYCS protein Paclitaxel results in increased expression of CYCS protein |
CTD |
PMID:10516758 PMID:14749477 PMID:15728126 PMID:15907983 PMID:16051289 PMID:16413505 PMID:17404021 PMID:18521433 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity |
ISO |
Paclitaxel results in increased activity of CYP19A1 protein |
CTD |
PMID:14691014 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Paclitaxel inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:11602686 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression decreases activity |
EXP ISO |
Paclitaxel results in increased expression of CYP1A2 mRNA Paclitaxel results in decreased activity of CYP1A2 protein |
CTD |
PMID:15585946 PMID:19909766 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in increased expression of CYP27B1 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 7:70,333,150...70,340,006
Ensembl chr 7:70,335,061...70,340,005
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases activity decreases activity |
ISO |
Paclitaxel results in increased activity of CYP2C9 protein Paclitaxel results in decreased activity of CYP2C9 protein |
CTD |
PMID:19202563 PMID:19909766 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c12 |
cytochrome P450, family 2, subfamily c, polypeptide 12 |
increases expression |
EXP |
Paclitaxel analog results in increased expression of CYP2C12 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 1:258,709,726...258,766,873
Ensembl chr 1:258,709,721...258,766,881
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases response to substance affects response to substance multiple interactions increases oxidation increases metabolic processing increases hydroxylation affects metabolic processing |
ISO |
CYP2C8 mRNA results in increased susceptibility to Paclitaxel CYP2C8 gene SNP affects the susceptibility to Paclitaxel Cyclohexenes analog inhibits the reaction [CYP2C8 protein results in increased metabolism of Paclitaxel]; perfluorooctane sulfonic acid inhibits the reaction [CYP2C8 protein results in increased hydroxylation of Paclitaxel]; sitaxsentan inhibits the reaction [CYP2C8 protein results in increased metabolism of Paclitaxel] CYP2C8 protein results in increased oxidation of Paclitaxel CYP2C8 protein affects the metabolism of Paclitaxel |
CTD |
PMID:12401345 PMID:12464242 PMID:15239142 PMID:15716363 PMID:15901749 PMID:15933212 PMID:16124035 PMID:17478480 PMID:17994679 PMID:19309152 PMID:20452209 PMID:21964418 PMID:23721565 PMID:27736846 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Paclitaxel results in decreased activity of CYP2D6 protein |
CTD |
PMID:19909766 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity multiple interactions |
EXP |
Paclitaxel results in decreased activity of CYP2E1 protein turmeric extract affects the reaction [Paclitaxel results in decreased activity of CYP2E1 protein] |
CTD |
PMID:24882083 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases activity increases oxidation increases expression affects metabolic processing multiple interactions decreases activity increases hydroxylation |
ISO EXP |
Paclitaxel results in increased activity of CYP3A4 protein CYP3A4 protein results in increased oxidation of Paclitaxel Paclitaxel results in increased expression of CYP3A4 protein Paclitaxel results in increased expression of CYP3A4 mRNA; Paclitaxel results in increased expression of CYP3A4 protein CYP3A4 protein affects the metabolism of Paclitaxel Plant Extracts inhibits the reaction [Paclitaxel results in increased expression of CYP3A4 protein] Ketoconazole inhibits the reaction [CYP3A4 protein results in increased oxidation of Paclitaxel]; Ketoconazole inhibits the reaction [Paclitaxel results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Paclitaxel results in increased expression of CYP3A4 protein]; Oxygen deficiency inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Paclitaxel] Paclitaxel results in decreased activity of CYP3A4 protein |
CTD |
PMID:12065438 PMID:12237780 PMID:15650019 PMID:15901749 PMID:15918522 PMID:16819505 PMID:17438109 PMID:18839173 PMID:19695866 PMID:19909766 PMID:23707768 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
increases expression |
EXP |
Paclitaxel results in increased expression of CYP4A22 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 5:134,492,734...134,507,158
Ensembl chr 5:134,492,756...134,507,154
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
EXP |
Paclitaxel results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Dapk1 |
death associated protein kinase 1 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in increased expression of DAPK1 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr17:4,297,038...4,454,941
Ensembl chr17:4,297,224...4,454,778
|
|
G |
Dbf4 |
DBF4 zinc finger |
decreases expression |
ISO |
Paclitaxel results in decreased expression of DBF4 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 4:22,898,527...22,914,091
Ensembl chr 4:22,898,527...22,914,177
|
|
G |
Dcn |
decorin |
decreases response to substance |
ISO |
DCN mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:25199881 |
|
NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
|
|
G |
Dctd |
dCMP deaminase |
affects response to substance |
ISO |
DCTD protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr16:47,177,144...47,222,850
Ensembl chr16:47,177,145...47,208,110
|
|
G |
Ddx23 |
DEAD-box helicase 23 |
affects response to substance |
ISO |
DDX23 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 7:140,325,453...140,342,730
Ensembl chr 7:140,325,431...140,342,727
|
|
G |
Dedd |
death effector domain-containing |
decreases expression |
ISO |
Paclitaxel results in decreased expression of DEDD mRNA |
CTD |
PMID:15000894 |
|
NCBI chr13:89,706,932...89,721,825
Ensembl chr13:89,718,066...89,721,454
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
decreases expression multiple interactions increases cleavage |
ISO |
Paclitaxel results in decreased expression of DFFA protein [Paclitaxel co-treated with Metformin] results in decreased expression of DFFA mRNA; [Tretinoin co-treated with Paclitaxel] results in increased cleavage of DFFA protein Paclitaxel results in increased cleavage of DFFA protein |
CTD |
PMID:15907983 PMID:17701358 PMID:18098270 PMID:29309887 |
|
NCBI chr 5:165,922,893...165,935,822
Ensembl chr 5:165,922,915...165,935,821
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
affects response to substance |
ISO |
DHCR24 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 5:126,164,708...126,188,926
Ensembl chr 5:126,164,674...126,191,206
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of DHCR7 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 1:217,018,916...217,034,890
Ensembl chr 1:217,018,916...217,034,904
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization increases expression multiple interactions |
ISO |
Paclitaxel affects the localization of DIABLO protein Paclitaxel results in increased expression of DIABLO protein [resveratrol co-treated with Paclitaxel] affects the localization of DIABLO protein; [Tretinoin co-treated with Paclitaxel] affects the localization of DIABLO protein; [Tretinoin co-treated with Paclitaxel] results in increased expression of DIABLO protein |
CTD |
PMID:14749477 PMID:17701358 PMID:18098270 |
|
NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
|
|
G |
Dmtf1 |
cyclin D binding myb-like transcription factor 1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of DMTF1 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 4:21,862,297...21,902,798
Ensembl chr 4:21,862,313...21,902,762
|
|
G |
Dnase1l3 |
deoxyribonuclease 1-like 3 |
decreases expression |
EXP |
Paclitaxel results in decreased expression of DNASE1L3 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr15:18,710,492...18,736,476
Ensembl chr15:18,710,492...18,736,473
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
affects expression decreases expression multiple interactions |
ISO |
Paclitaxel affects the expression of DPYD mRNA Paclitaxel results in decreased expression of DPYD mRNA [Paclitaxel co-treated with doxifluridine] affects the expression of DPYD mRNA |
CTD |
PMID:16568373 PMID:18630517 |
|
NCBI chr 2:221,823,692...222,694,627
Ensembl chr 2:221,823,687...222,694,627
|
|
G |
Dsp |
desmoplakin |
affects response to substance |
ISO |
DSP protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr17:27,286,811...27,334,453
Ensembl chr17:27,286,796...27,334,379
|
|
G |
Dst |
dystonin |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] affects the expression of DST mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 9:37,902,336...38,296,961
Ensembl chr 9:37,902,303...38,196,273
|
|
G |
Dusp3 |
dual specificity phosphatase 3 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of DUSP3 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr10:89,904,578...89,918,296
Ensembl chr10:89,904,560...89,918,427
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases response to substance |
ISO |
E2F1 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16849574 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
E2f3 |
E2F transcription factor 3 |
multiple interactions |
ISO |
E2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr17:36,334,136...36,408,831
Ensembl chr17:36,334,147...36,408,831
|
|
G |
E2f4 |
E2F transcription factor 4 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of E2F4 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr19:37,252,828...37,260,239
Ensembl chr19:37,252,843...37,260,239
|
|
G |
E2f5 |
E2F transcription factor 5 |
increases expression |
ISO |
Paclitaxel results in increased expression of E2F5 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 2:88,350,764...88,366,913
Ensembl chr 2:88,351,361...88,366,115
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
increases expression |
EXP |
Paclitaxel results in increased expression of ECH1 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 1:87,009,798...87,015,996
Ensembl chr 1:87,009,730...87,016,005
|
|
G |
Ecm1 |
extracellular matrix protein 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] affects the expression of ECM1 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 2:197,855,468...197,860,973
Ensembl chr 2:197,855,460...197,860,699
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of EEF2 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 7:11,401,501...11,406,771
Ensembl chr 7:11,401,501...11,406,771
|
|
G |
Efcab7 |
EF-hand calcium binding domain 7 |
affects response to substance |
ISO |
EFCAB7 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 5:118,673,835...118,724,581
Ensembl chr 5:118,541,979...118,724,581
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of EFEMP1 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr14:113,202,382...113,294,993
Ensembl chr14:113,202,419...113,295,014
|
|
G |
Efna1 |
ephrin A1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of EFNA1 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
|
|
G |
Egf |
epidermal growth factor |
multiple interactions decreases expression |
ISO |
Paclitaxel inhibits the reaction [EGF protein results in increased expression of PSA mRNA] Paclitaxel results in decreased expression of EGF mRNA |
CTD |
PMID:18058816 PMID:20807808 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egfl6 |
EGF-like-domain, multiple 6 |
decreases response to substance |
ISO |
EGFL6 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:25199881 |
|
NCBI chr X:29,430,789...29,488,737
Ensembl chr X:29,430,831...29,488,739
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation decreases expression |
ISO |
[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein; Paclitaxel promotes the reaction [HER3 protein binds to EGFR protein] Paclitaxel results in increased phosphorylation of EGFR protein Paclitaxel results in decreased expression of EGFR mRNA |
CTD |
PMID:16211241 PMID:16413505 PMID:18058816 PMID:20726858 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Ehf |
ets homologous factor |
decreases expression |
ISO |
Paclitaxel results in decreased expression of EHF mRNA |
CTD |
PMID:19682730 |
|
NCBI chr 3:93,176,257...93,216,484
Ensembl chr 3:93,178,163...93,216,495
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
affects response to substance |
ISO |
EIF2AK3 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
affects phosphorylation |
ISO |
Paclitaxel affects the phosphorylation of EIF2S1 protein |
CTD |
PMID:29053414 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Eif4a1 |
eukaryotic translation initiation factor 4A1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of EIF4A1 protein |
CTD |
PMID:15907983 |
|
NCBI chr10:56,271,257...56,276,764
Ensembl chr10:56,271,257...56,276,764
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
increases response to substance |
ISO |
EIF5A protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr10:56,527,075...56,531,615
Ensembl chr10:56,527,085...56,531,483
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of ELK1 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr X:1,287,875...1,304,822
Ensembl chr X:1,297,099...1,304,822
|
|
G |
Elmo3 |
engulfment and cell motility 3 |
increases expression |
ISO |
Paclitaxel results in increased expression of ELMO3 protein |
CTD |
PMID:15907983 |
|
NCBI chr19:37,260,330...37,264,832
Ensembl chr19:37,260,469...37,264,829
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
EXP |
Paclitaxel results in increased expression of EMP1 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 4:169,161,076...169,181,967
Ensembl chr 4:169,147,243...169,181,966
|
|
G |
Emp3 |
epithelial membrane protein 3 |
increases expression |
ISO |
Paclitaxel results in increased expression of EMP3 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr 1:101,900,731...101,903,948
Ensembl chr 1:101,900,733...101,903,910
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
increases expression |
ISO |
Paclitaxel results in increased expression of ENPP2 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001
|
|
G |
Epcam |
epithelial cell adhesion molecule |
multiple interactions decreases expression increases expression |
ISO |
[Paclitaxel co-treated with Carboplatin] results in increased expression of EPCAM protein Paclitaxel results in decreased expression of EPCAM mRNA; Paclitaxel results in decreased expression of EPCAM protein Paclitaxel results in increased expression of EPCAM protein |
CTD |
PMID:12695858 PMID:15907983 PMID:19682730 |
|
NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases expression |
EXP |
Paclitaxel results in increased expression of EPHX2 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
G |
Epo |
erythropoietin |
decreases response to substance |
ISO |
EPO protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:17010629 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases response to substance affects response to substance |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel]; 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel]; [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Paclitaxel; Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Paclitaxel]; Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein ERBB2 protein results in decreased susceptibility to Paclitaxel; ERBB2 results in decreased susceptibility to Paclitaxel ERBB2 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:10327070 PMID:16580691 PMID:21712253 PMID:25866362 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases response to substance |
ISO |
ERBB3 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
ERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 9:75,021,790...76,178,936
Ensembl chr 9:75,021,790...75,528,644
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
increases expression |
ISO |
Paclitaxel results in increased expression of ERCC5 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 9:50,928,847...50,970,962
Ensembl chr 9:50,925,619...50,970,955
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases expression |
ISO |
alitretinoin inhibits the reaction [Paclitaxel results in increased expression of ESR1 mRNA]; beta Carotene inhibits the reaction [Paclitaxel results in increased expression of ESR1 mRNA]; Paclitaxel inhibits the reaction [Tamoxifen binds to ESR1 protein]; Vitamin A inhibits the reaction [Paclitaxel results in increased expression of ESR1 mRNA] |
CTD |
PMID:15283693 PMID:19340624 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression decreases expression multiple interactions |
ISO |
Paclitaxel results in increased expression of ESR2 mRNA Paclitaxel results in decreased expression of ESR2 mRNA alitretinoin inhibits the reaction [Paclitaxel results in increased expression of ESR2 mRNA] |
CTD |
PMID:19340624 PMID:23956100 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
F13a1 |
coagulation factor XIII A1 chain |
increases expression |
EXP |
Paclitaxel results in increased expression of F13A1 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr17:28,504,650...28,680,015
Ensembl chr17:28,504,623...28,680,362
|
|
G |
F2 |
coagulation factor II |
multiple interactions |
ISO |
[Paclitaxel co-treated with F2 protein] affects the localization of RELA protein; [Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein; [Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA; [Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein; [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein; [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] |
CTD |
PMID:19944065 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein; [Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA; [Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein]; pyrazolanthrone inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] |
CTD |
PMID:19944065 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of FABP1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions increases phosphorylation increases expression |
ISO |
pyrazolanthrone inhibits the reaction [Paclitaxel results in increased phosphorylation of FADD protein] Paclitaxel results in increased expression of FADD mRNA |
CTD |
PMID:16450001 PMID:18058816 |
|
NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
|
|
G |
Fam234b |
family with sequence similarity 234, member B |
multiple interactions |
ISO |
FAM234B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 4:168,976,797...169,052,750
Ensembl chr 4:168,976,859...169,019,561
|
|
G |
Fam3c |
FAM3 metabolism regulating signaling molecule C |
affects response to substance |
ISO |
FAM3C protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 4:49,388,962...49,439,892
Ensembl chr 4:49,387,989...49,439,867
|
|
G |
Fancl |
FA complementation group L |
affects response to substance |
ISO |
FANCL protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr14:110,675,306...110,740,880
Ensembl chr14:110,676,090...110,740,317
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression decreases expression increases response to substance |
ISO |
[esculetin co-treated with Paclitaxel] results in increased expression of FAS protein; cacalol promotes the reaction [Paclitaxel results in decreased expression of FAS mRNA]; Paclitaxel promotes the reaction [cacalol results in decreased expression of FAS mRNA] Paclitaxel results in increased expression of FAS mRNA Paclitaxel results in increased expression of FAS protein FAS protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16051289 PMID:17449502 PMID:18074150 PMID:20665104 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression increases response to substance |
ISO |
[esculetin co-treated with Paclitaxel] results in increased expression of FASLG protein; TYMP inhibits the reaction [Paclitaxel results in increased expression of FASLG mRNA]; TYMP inhibits the reaction [Paclitaxel results in increased expression of FASLG protein] Paclitaxel results in increased expression of FASLG mRNA; Paclitaxel results in increased expression of FASLG protein FASLG protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:10502406 PMID:11716366 PMID:15907805 PMID:16051289 PMID:18074150 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
Paclitaxel results in decreased expression of FASN protein |
CTD |
PMID:30667213 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fbn1 |
fibrillin 1 |
increases expression |
ISO |
Paclitaxel results in increased expression of FBN1 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr 3:117,569,708...117,766,160
Ensembl chr 3:117,569,697...117,766,120
|
|
G |
Fbxo5 |
F-box protein 5 |
affects expression |
ISO |
Paclitaxel affects the expression of FBXO5 protein |
CTD |
PMID:27769712 |
|
NCBI chr 1:42,461,277...42,467,646
Ensembl chr 1:42,461,291...42,467,586
|
|
G |
Fcgr2a |
Fc fragment of IgG receptor IIa |
increases expression |
EXP |
Paclitaxel results in increased expression of FCGR3 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr13:91,146,878...91,163,691
Ensembl chr13:91,168,973...91,198,036 Ensembl chr13:91,168,973...91,198,036
|
|
G |
Fcgr2b |
Fc fragment of IgG receptor IIb |
increases expression |
EXP |
Paclitaxel results in increased expression of FCGR2B mRNA |
CTD |
PMID:18754875 |
|
NCBI chr13:89,329,298...89,343,916
Ensembl chr13:89,327,794...89,433,815
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
affects response to substance |
ISO |
FDFT1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr15:46,339,248...46,367,302
Ensembl chr15:46,339,249...46,367,302
|
|
G |
Fdps |
farnesyl diphosphate synthase |
increases response to substance |
ISO |
FDPS mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr 2:188,403,595...188,413,219
Ensembl chr 2:188,392,858...188,413,219
|
|
G |
Fgb |
fibrinogen beta chain |
decreases expression |
EXP |
Paclitaxel results in decreased expression of FGB mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 2:182,028,044...182,035,026
Ensembl chr 2:182,027,115...182,038,178
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases response to substance |
ISO |
FGF2 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16741658 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
affects response to substance |
ISO |
FGF5 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr14:12,974,921...12,996,046
Ensembl chr14:12,974,921...12,995,584
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of FGF7 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
|
|
G |
Fgfbp1 |
fibroblast growth factor binding protein 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of FGFBP1 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr14:71,647,429...71,650,359
Ensembl chr14:71,649,274...71,650,354
|
|
G |
Fgfrl1 |
fibroblast growth factor receptor-like 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of FGFRL1 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr14:2,020,110...2,032,169
Ensembl chr14:2,018,500...2,032,593
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
increases response to substance |
ISO |
FHL1 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr X:159,112,516...159,172,528
Ensembl chr X:159,112,880...159,172,524
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression |
EXP |
Paclitaxel results in increased expression of FIS1 protein |
CTD |
PMID:26732598 |
|
NCBI chr12:22,750,485...22,765,324
Ensembl chr12:22,750,485...22,765,308
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in increased expression of FKBP1A mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 3:147,042,944...147,062,725
Ensembl chr 3:147,042,944...147,062,724
|
|
G |
Fkbp3 |
FKBP prolyl isomerase 3 |
increases expression |
ISO |
Paclitaxel results in increased expression of FKBP3 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 6:86,810,865...86,822,115
Ensembl chr 6:86,810,809...86,822,094
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
increases expression |
ISO |
Paclitaxel results in increased expression of FLT1 |
CTD |
PMID:21975929 |
|
NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of FN1 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP |
Paclitaxel results in increased expression of FOSB protein alternative form 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine inhibits the reaction [Paclitaxel results in increased expression of FOSB protein alternative form] |
CTD |
PMID:30414958 |
|
NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
|
|
G |
Fras1 |
Fraser extracellular matrix complex subunit 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of FRAS1 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr14:14,438,392...14,853,016
Ensembl chr14:14,439,082...14,689,554
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
increases response to substance |
ISO |
FSCN1 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr12:13,655,459...13,668,595
Ensembl chr12:13,656,554...13,668,515
|
|
G |
Fshr |
follicle stimulating hormone receptor |
decreases expression |
ISO |
Paclitaxel results in decreased expression of FSHR mRNA |
CTD |
PMID:23956100 |
|
NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
|
|
G |
Fth1 |
ferritin heavy chain 1 |
decreases response to substance |
ISO |
FTH1 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Ftl1 |
ferritin light chain 1 |
decreases response to substance |
ISO |
FTL mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases response to substance |
ISO |
FURIN mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr 1:142,185,092...142,198,167
Ensembl chr 1:142,185,094...142,197,182
|
|
G |
Fxyd3 |
FXYD domain-containing ion transport regulator 3 |
increases response to substance decreases expression |
ISO |
FXYD3 mRNA results in increased susceptibility to Paclitaxel Paclitaxel results in decreased expression of FXYD3 mRNA |
CTD |
PMID:16322897 PMID:19682730 |
|
NCBI chr 1:89,502,561...89,510,146
Ensembl chr 1:89,502,562...89,509,343
|
|
G |
G0s2 |
G0/G1switch 2 |
increases expression |
EXP |
Paclitaxel analog results in increased expression of G0S2 mRNA; Paclitaxel results in increased expression of G0S2 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr13:112,004,140...112,005,052
Ensembl chr13:112,004,140...112,005,052
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
increases expression |
EXP |
Paclitaxel results in increased expression of G6PC1 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression decreases response to substance |
ISO |
[Paclitaxel results in increased expression of TP53 protein] which results in increased expression of GADD45A mRNA GADD45A mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:9041188 PMID:16322897 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Galnt7 |
polypeptide N-acetylgalactosaminyltransferase 7 |
affects response to substance |
ISO |
GALNT7 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr16:35,935,059...36,062,734
Ensembl chr16:35,934,970...36,062,719
|
|
G |
Gamt |
guanidinoacetate N-methyltransferase |
multiple interactions |
ISO |
GAMT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 7:12,314,848...12,317,998
Ensembl chr 7:12,314,848...12,317,998
|
|
G |
Gchfr |
GTP cyclohydrolase I feedback regulator |
decreases response to substance |
ISO |
GCHFR protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 3:110,975,923...110,979,957
Ensembl chr 3:110,975,923...110,979,957
|
|
G |
Gckr |
glucokinase regulator |
increases expression |
EXP |
Paclitaxel results in increased expression of GCKR mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 6:26,355,296...26,385,761
Ensembl chr 6:26,355,296...26,385,761
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions increases expression |
ISO EXP |
[Tretinoin co-treated with Paclitaxel] results in increased expression of GFAP protein Paclitaxel results in increased expression of GFAP protein |
CTD |
PMID:16854522 PMID:17005179 PMID:18098270 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
decreases response to substance |
ISO |
GFPT1 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 4:118,852,046...118,901,583
Ensembl chr 4:118,852,062...118,901,591
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions |
ISO |
GFRA1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 1:279,203,046...279,572,789
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
increases expression |
EXP |
Paclitaxel results in increased expression of GJB2 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr15:37,377,313...37,394,494
Ensembl chr15:37,377,316...37,383,277
|
|
G |
Gjb6 |
gap junction protein, beta 6 |
increases expression |
EXP |
Paclitaxel results in increased expression of GJB6 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr15:37,400,888...37,411,656
Ensembl chr15:37,400,889...37,410,848
|
|
G |
Gna13 |
G protein subunit alpha 13 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of GNA13 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr10:97,647,196...97,680,030
Ensembl chr10:97,647,111...97,684,730
|
|
G |
Gpc3 |
glypican 3 |
increases response to substance |
ISO |
GPC3 mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:25199881 |
|
NCBI chr X:139,579,268...139,947,093
Ensembl chr X:139,579,268...139,916,883
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
affects response to substance |
ISO |
GPI protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 1:90,063,411...90,091,287
Ensembl chr 1:90,063,411...90,091,287
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
EXP |
Paclitaxel results in increased expression of GPNMB mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683
|
|
G |
Gpr35 |
G protein-coupled receptor 35 |
decreases response to substance |
ISO |
GPR35 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 9:100,129,428...100,141,269
Ensembl chr 9:100,137,881...100,138,801
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
multiple interactions increases expression |
EXP |
1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine inhibits the reaction [Paclitaxel results in increased expression of GRIA1 protein] |
CTD |
PMID:30414958 |
|
NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions increases expression |
EXP |
1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine inhibits the reaction [Paclitaxel results in increased expression of GRIN2B protein] |
CTD |
PMID:30414958 |
|
NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation |
ISO |
Paclitaxel results in increased phosphorylation of GSK3B protein |
CTD |
PMID:19426673 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsn |
gelsolin |
decreases expression |
ISO |
Paclitaxel results in decreased expression of GSN mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 3:14,456,106...14,508,922
Ensembl chr 3:14,467,330...14,508,911
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
GSTM1 gene polymorphism affects the susceptibility to [Paclitaxel co-treated with Cisplatin] |
CTD |
PMID:12851839 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm3l |
glutathione S-transferase mu 3-like |
decreases response to substance |
ISO |
GSTM5 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr 2:210,761,729...210,766,501
Ensembl chr 2:210,761,729...210,766,501
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
affects response to substance increases response to substance |
ISO |
GSTP1 protein affects the susceptibility to Paclitaxel GSTP1 mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:15239142 PMID:16217747 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
multiple interactions |
ISO |
GSTT1 gene polymorphism affects the susceptibility to [Paclitaxel co-treated with Cisplatin] |
CTD |
PMID:12851839 |
|
NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
|
|
G |
Gtf2a2 |
general transcription factor 2A subunit 2 |
increases expression |
EXP |
Paclitaxel analog results in increased expression of GTF2A2 mRNA; Paclitaxel results in increased expression of GTF2A2 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 8:76,422,341...76,435,587
Ensembl chr 8:76,422,359...76,435,473
|
|
G |
Gtf2i |
general transcription factor II I |
decreases expression |
ISO |
Paclitaxel results in decreased expression of GTF2I mRNA |
CTD |
PMID:15000894 |
|
NCBI chr12:25,410,804...25,487,970
Ensembl chr12:25,411,207...25,488,156
|
|
G |
Gtse1 |
G-2 and S-phase expressed 1 |
increases expression |
ISO |
Paclitaxel results in increased expression of GTSE1 protein |
CTD |
PMID:15907983 |
|
NCBI chr 7:126,736,416...126,753,221
Ensembl chr 7:126,736,732...126,753,220
|
|
G |
Gusb |
glucuronidase, beta |
affects response to substance |
ISO |
GUSB protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
|
|
G |
H2ax |
H2A.X variant histone |
increases expression multiple interactions |
ISO |
Paclitaxel results in increased expression of H2AX protein; Paclitaxel results in increased expression of H2AX protein modified form palbociclib inhibits the reaction [Paclitaxel results in increased expression of H2AX protein] |
CTD |
PMID:18451153 PMID:22302033 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hacl1 |
2-hydroxyacyl-CoA lyase 1 |
increases expression |
EXP |
Paclitaxel results in increased expression of HACL1 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr16:7,720,047...7,758,119
Ensembl chr16:7,714,465...7,758,189
|
|
G |
Hdac4 |
histone deacetylase 4 |
decreases expression |
EXP |
Paclitaxel results in decreased expression of HDAC4 protein |
CTD |
PMID:27474498 |
|
NCBI chr 9:99,052,945...99,299,715
Ensembl chr 9:99,057,089...99,299,715
|
|
G |
Hdac9 |
histone deacetylase 9 |
increases response to substance |
ISO |
HDAC9 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 6:53,487,367...54,358,694
Ensembl chr 6:53,488,883...54,059,119
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCB1 protein]; HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCC1 protein]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in decreased expression of BCL2 protein]]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in increased expression of BAX protein]] |
CTD |
PMID:29341321 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
decreases expression |
EXP |
Paclitaxel results in decreased expression of HMBS mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 8:48,667,278...48,674,673
Ensembl chr 8:48,667,275...48,674,748
|
|
G |
Hmcn1 |
hemicentin 1 |
increases response to substance |
ISO |
HMCN1 mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:25199881 |
|
NCBI chr13:67,799,791...68,360,664
Ensembl chr13:67,799,791...68,360,664
|
|
G |
Hmgb1 |
high mobility group box 1 |
affects response to substance decreases expression |
ISO EXP |
HMGB1 protein affects the susceptibility to Paclitaxel Paclitaxel results in decreased expression of HMGB1 protein |
CTD |
PMID:16217747 PMID:27474498 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
EXP |
Paclitaxel results in increased expression of HMGCS2 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
|
|
G |
Hmgn3 |
high mobility group nucleosomal binding domain 3 |
affects response to substance |
ISO |
HMGN3 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 8:90,628,203...90,665,055
Ensembl chr 8:90,628,209...90,664,554
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
ISO |
Paclitaxel results in decreased expression of HMMR protein |
CTD |
PMID:15907983 |
|
NCBI chr10:25,861,490...25,890,639
Ensembl chr10:25,861,490...25,890,639
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of HNRNPA2B1 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 4:81,237,496...81,241,281
Ensembl chr 4:81,237,496...81,241,282
|
|
G |
Hnrnpab |
heterogeneous nuclear ribonucleoprotein A/B |
decreases expression |
ISO |
Paclitaxel results in decreased expression of HNRNPAB mRNA |
CTD |
PMID:15000894 |
|
NCBI chr10:34,955,713...34,961,662
Ensembl chr10:34,955,716...34,961,608
|
|
G |
Hnrnph1 |
heterogeneous nuclear ribonucleoprotein H1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of HNRNPH1 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr10:35,872,619...35,879,911
Ensembl chr10:35,870,232...35,879,910
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of HNRNPK mRNA |
CTD |
PMID:29309887 |
|
NCBI chr17:6,664,730...6,676,753
Ensembl chr17:6,665,659...6,676,654
|
|
G |
Hook1 |
hook microtubule-tethering protein 1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of HOOK1 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr 5:114,940,053...115,000,691
Ensembl chr 5:114,940,053...115,000,691
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of HRAS mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
affects response to substance |
ISO |
HSD17B4 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr18:44,810,462...44,897,677
Ensembl chr18:44,810,388...44,897,640
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
increases expression |
EXP |
Paclitaxel analog results in increased expression of HSPA1L mRNA |
CTD |
PMID:15585946 |
|
NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Paclitaxel results in increased expression of HSPA5 protein |
CTD |
PMID:26732598 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspb3 |
heat shock protein family B (small) member 3 |
increases expression |
ISO |
Paclitaxel results in increased expression of HSPB3 protein |
CTD |
PMID:15907983 |
|
NCBI chr 2:45,517,788...45,518,502
Ensembl chr 2:45,517,789...45,518,502
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
Curcumin inhibits the reaction [Paclitaxel results in increased expression of ICAM1 protein] Paclitaxel results in decreased expression of ICAM1 mRNA; Paclitaxel results in decreased expression of ICAM1 protein |
CTD |
PMID:12649748 PMID:16243823 PMID:18058816 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
affects response to substance decreases expression |
ISO |
IDH2 protein affects the susceptibility to Paclitaxel Paclitaxel results in decreased expression of IDH2 mRNA |
CTD |
PMID:15000894 PMID:16217747 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Ier3 |
immediate early response 3 |
increases expression |
ISO |
Paclitaxel results in increased expression of IER3 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
|
|
G |
Ifi30 |
IFI30, lysosomal thiol reductase |
decreases response to substance |
ISO |
IFI30 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr16:20,426,566...20,430,772
Ensembl chr16:20,426,566...20,430,752
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in increased expression of IFNG mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
multiple interactions increases expression |
ISO |
IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] Paclitaxel results in increased expression of IGFBP4 mRNA |
CTD |
PMID:16896004 PMID:19682730 |
|
NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
|
|
G |
Igfbp6 |
insulin-like growth factor binding protein 6 |
increases expression |
EXP |
Paclitaxel results in increased expression of IGFBP6 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 7:143,749,385...143,754,018
Ensembl chr 7:143,749,221...143,754,054
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
affects response to substance multiple interactions |
ISO |
IKBKB protein affects the susceptibility to Paclitaxel [Paclitaxel co-treated with Metformin] results in decreased expression of IKBKB mRNA |
CTD |
PMID:20159942 PMID:29309887 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il10 |
interleukin 10 |
increases expression multiple interactions |
ISO EXP |
Paclitaxel results in increased expression of IL10 protein [1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine co-treated with Paclitaxel] results in increased expression of IL10 protein |
CTD |
PMID:14698135 PMID:30414958 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12a |
interleukin 12A |
multiple interactions increases expression |
ISO |
CD14 protein affects the reaction [Paclitaxel results in increased expression of IL12A mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased expression of IL12A mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased secretion of [IL12A protein binds to IL12B protein]]; Paclitaxel results in increased secretion of [IL12A protein binds to IL12B protein]; TLR4 protein affects the reaction [Paclitaxel results in increased expression of IL12A mRNA] |
CTD |
PMID:11123339 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression |
ISO |
CD14 protein affects the reaction [Paclitaxel results in increased expression of IL12B mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased secretion of [IL12A protein binds to IL12B protein]]; Paclitaxel results in increased secretion of [IL12A protein binds to IL12B protein]; TLR4 protein affects the reaction [Paclitaxel results in increased expression of IL12B mRNA] |
CTD |
PMID:11123339 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il13ra2 |
interleukin 13 receptor subunit alpha 2 |
affects response to substance |
ISO |
IL13RA2 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr X:118,443,955...118,514,716
Ensembl chr X:118,443,823...118,513,061
|
|
G |
Il17rb |
interleukin 17 receptor B |
decreases response to substance |
ISO |
IL17RB protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr16:6,064,287...6,077,978
Ensembl chr16:6,064,288...6,077,978
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of IL18 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP ISO |
Paclitaxel results in increased expression of IL1B mRNA |
CTD |
PMID:17174526 PMID:28242239 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of IL1R1 protein |
CTD |
PMID:15907983 |
|
NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions affects response to substance |
ISO EXP |
Paclitaxel results in increased expression of IL6 protein [Paclitaxel co-treated with IL6 protein] results in increased expression of ABCB1 protein; [Paclitaxel co-treated with IL6 protein] results in increased expression of ABCC1 protein; HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCB1 protein]; HIF1A protein affects the reaction [[Paclitaxel co-treated with IL6 protein] results in increased expression of ABCC1 protein]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in decreased expression of BCL2 protein]]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Paclitaxel results in increased expression of BAX protein]]; IL6 protein inhibits the reaction [Paclitaxel results in decreased expression of BCL2 protein]; IL6 protein inhibits the reaction [Paclitaxel results in increased expression of BAX protein] TLR4 protein mutant form inhibits the reaction [Paclitaxel results in increased expression of IL6 mRNA] IL6 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:14698135 PMID:18270703 PMID:28242239 PMID:29341321 PMID:30414958 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Insig1 |
insulin induced gene 1 |
affects response to substance |
ISO |
INSIG1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
|
|
G |
Ip6k1 |
inositol hexakisphosphate kinase 1 |
decreases expression |
EXP |
Paclitaxel results in decreased expression of IP6K1 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 8:116,781,957...116,826,152
Ensembl chr 8:116,804,451...116,823,540
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of IRF3 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
|
|
G |
Irf5 |
interferon regulatory factor 5 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in increased expression of IRF5 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 4:56,804,477...56,816,271
Ensembl chr 4:56,805,132...56,820,543
|
|
G |
Irf7 |
interferon regulatory factor 7 |
increases expression multiple interactions |
EXP ISO |
Paclitaxel results in increased expression of IRF7 mRNA [Paclitaxel co-treated with Metformin] results in increased expression of IRF7 mRNA |
CTD |
PMID:15585946 PMID:29309887 |
|
NCBI chr 1:214,249,388...214,252,909
Ensembl chr 1:214,248,837...214,252,456
|
|
G |
Irf8 |
interferon regulatory factor 8 |
increases expression multiple interactions |
ISO EXP |
Paclitaxel results in increased expression of IRF8 mRNA Paclitaxel results in increased expression of IRF8 mRNA; Paclitaxel results in increased expression of IRF8 protein 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine inhibits the reaction [Paclitaxel results in increased expression of IRF8 mRNA]; 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine inhibits the reaction [Paclitaxel results in increased expression of IRF8 protein]; Paclitaxel promotes the reaction [RELA protein binds to IRF8 promoter] TLR4 protein affects the reaction [Paclitaxel results in increased expression of IRF8 mRNA] |
CTD |
PMID:11123339 PMID:30414958 |
|
NCBI chr19:54,314,859...54,336,643
Ensembl chr19:54,314,865...54,336,640
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
affects response to substance |
ISO |
ISG15 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 5:173,624,862...173,629,124
Ensembl chr 5:173,624,310...173,626,248
|
|
G |
Itga1 |
integrin subunit alpha 1 |
increases response to substance |
ISO |
ITGA1 mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:25199881 |
|
NCBI chr 2:47,127,403...47,281,387
Ensembl chr 2:47,127,219...47,281,421
|
|
G |
Itga2 |
integrin subunit alpha 2 |
increases response to substance |
EXP |
ITGA2 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:18234883 |
|
NCBI chr 2:46,996,904...47,097,011
Ensembl chr 2:47,000,323...47,096,961
|
|
G |
Itgal |
integrin subunit alpha L |
decreases expression |
ISO |
Paclitaxel results in decreased expression of ITGAL mRNA; Paclitaxel results in decreased expression of ITGAL protein |
CTD |
PMID:12649748 |
|
NCBI chr 1:198,744,053...198,781,745
Ensembl chr 1:198,744,050...198,781,750
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions increases expression |
ISO EXP |
ITGAM protein affects the reaction [Paclitaxel affects the localization of and results in increased activity of [NFKB1 protein binds to RELA protein]]; ITGAM protein affects the reaction [Paclitaxel results in increased expression of IL12A mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased expression of PTGS2 mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK8 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased secretion of [IL12A protein binds to IL12B protein]] Paclitaxel results in increased expression of ITGAM mRNA |
CTD |
PMID:11123339 PMID:17174526 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Itgb1 |
integrin subunit beta 1 |
increases response to substance |
EXP |
ITGB1 results in increased susceptibility to Paclitaxel |
CTD |
PMID:14984413 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Itgb1bp1 |
integrin subunit beta 1 binding protein 1 |
affects response to substance |
ISO |
ITGB1BP1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 6:43,348,927...43,363,633
Ensembl chr 6:43,348,958...43,363,335
|
|
G |
Itgb5 |
integrin subunit beta 5 |
decreases response to substance |
ISO |
ITGB5 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr11:70,056,500...70,172,164
Ensembl chr11:70,056,500...70,172,372
|
|
G |
Itgb6 |
integrin subunit beta 6 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of ITGB6 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr 3:46,652,624...46,775,362
Ensembl chr 3:46,652,623...46,726,958
|
|
G |
Itih2 |
inter-alpha-trypsin inhibitor heavy chain 2 |
increases expression |
ISO |
Paclitaxel results in increased expression of ITIH2 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr17:72,160,734...72,197,248
Ensembl chr17:72,160,735...72,195,509
|
|
G |
Itm2b |
integral membrane protein 2B |
affects response to substance |
ISO |
ITM2B protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr15:55,254,703...55,277,713
Ensembl chr15:55,254,706...55,277,713
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases phosphorylation increases expression |
ISO EXP |
Paclitaxel results in increased phosphorylation of JUN protein Paclitaxel results in increased expression of JUN protein |
CTD |
PMID:15585644 PMID:17686523 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kcnj16 |
potassium inwardly-rectifying channel, subfamily J, member 16 |
increases expression |
EXP |
Paclitaxel results in increased expression of KCNJ16 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr10:99,330,894...99,391,551
Ensembl chr10:99,388,130...99,389,898
|
|
G |
Kcnk3 |
potassium two pore domain channel subfamily K member 3 |
increases expression |
ISO |
Paclitaxel results in increased expression of KCNK3 protein |
CTD |
PMID:15907983 |
|
NCBI chr 6:27,154,274...27,190,209
Ensembl chr 6:27,151,612...27,190,132
|
|
G |
Kcnma1 |
potassium calcium-activated channel subfamily M alpha 1 |
affects response to substance |
ISO |
KCNMA1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr15:344,204...1,048,849
Ensembl chr15:344,360...1,047,956
|
|
G |
Kdm4b |
lysine demethylase 4B |
multiple interactions |
ISO |
KDM4B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 9:10,656,035...10,734,127
Ensembl chr 9:10,653,216...10,734,073
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
[KEAP1 protein results in decreased stability of NFE2L2 protein] which results in increased susceptibility to Paclitaxel |
CTD |
PMID:20530669 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Kif3a |
kinesin family member 3a |
multiple interactions |
ISO |
KIF3A mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:38,918,705...38,953,958
Ensembl chr10:38,918,748...38,952,785
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of KIT mRNA; [Cisplatin co-treated with Paclitaxel] results in increased expression of KIT protein |
CTD |
PMID:20705681 |
|
NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of KRAS mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
|
|
G |
Krt13 |
keratin 13 |
decreases response to substance |
ISO |
KRT13 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr10:88,032,130...88,036,040
Ensembl chr10:88,032,130...88,036,040
|
|
G |
Krt18 |
keratin 18 |
increases expression |
ISO |
Paclitaxel results in increased expression of KRT18 protein modified form |
CTD |
PMID:22907900 |
|
NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
|
|
G |
Krt19 |
keratin 19 |
increases expression |
EXP |
Paclitaxel results in increased expression of KRT19 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr10:88,055,843...88,060,560
Ensembl chr10:88,055,841...88,060,561
|
|
G |
Krt23 |
keratin 23 |
increases response to substance |
ISO |
KRT23 mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:25199881 |
|
NCBI chr10:87,391,623...87,407,634
Ensembl chr10:87,391,623...87,407,634
|
|
G |
Krt7 |
keratin 7 |
increases response to substance |
ISO |
KRT7 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 7:143,059,731...143,075,907
Ensembl chr 7:143,059,764...143,075,907
|
|
G |
Lama2 |
laminin subunit alpha 2 |
increases response to substance |
ISO |
LAMA2 mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:25199881 |
|
NCBI chr 1:18,491,264...19,143,486
Ensembl chr 1:18,491,384...19,143,269
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
affects response to substance |
ISO |
LAMP2 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr X:124,722,628...124,766,079
Ensembl chr X:124,722,628...124,766,044
|
|
G |
Lbp |
lipopolysaccharide binding protein |
increases expression |
EXP |
Paclitaxel results in increased expression of LBP mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 3:154,786,232...154,812,910
Ensembl chr 3:154,786,215...154,813,464
|
|
G |
Lcp2 |
lymphocyte cytosolic protein 2 |
increases expression |
ISO |
Paclitaxel results in increased expression of LCP2 protein |
CTD |
PMID:15907983 |
|
NCBI chr10:18,996,523...19,043,289
Ensembl chr10:18,996,523...19,043,286
|
|
G |
Ldha |
lactate dehydrogenase A |
increases response to substance increases expression multiple interactions |
ISO EXP |
LDHA mutant form results in increased susceptibility to Paclitaxel Paclitaxel analog results in increased expression of LDHA mRNA; Paclitaxel results in increased expression of LDHA mRNA [Oxamic Acid results in decreased activity of LDHA protein] which results in increased susceptibility to Paclitaxel |
CTD |
PMID:15585946 PMID:21332213 |
|
NCBI chr 1:102,900,288...102,909,713
Ensembl chr 1:102,900,286...102,909,707
|
|
G |
Ldlr |
low density lipoprotein receptor |
affects response to substance |
ISO |
LDLR protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
G |
Lgals4 |
galectin 4 |
decreases response to substance |
ISO |
LGALS4 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 1:87,019,598...87,027,720
Ensembl chr 1:87,019,975...87,027,691
|
|
G |
Lifr |
LIF receptor subunit alpha |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of LIFR mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 2:56,424,910...56,489,346
Ensembl chr 2:56,426,367...56,489,415
|
|
G |
Lig1 |
DNA ligase 1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of LIG1 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 1:75,356,212...75,394,757
Ensembl chr 1:75,356,220...75,394,758
|
|
G |
Lilrb4 |
leukocyte immunoglobulin like receptor B4 |
increases expression |
EXP |
Paclitaxel results in increased expression of LILRB4 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 1:73,393,854...73,399,448
Ensembl chr 1:73,393,850...73,399,579
|
|
G |
Lingo3 |
leucine rich repeat and Ig domain containing 3 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in increased expression of LINGO3 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 7:11,737,293...11,746,703
Ensembl chr 7:11,737,293...11,746,703
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
affects response to substance |
ISO |
LITAF protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr10:4,753,546...4,763,272
Ensembl chr10:4,719,713...4,763,510
|
|
G |
Lox |
lysyl oxidase |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of LOX mRNA |
CTD |
PMID:20705681 |
|
NCBI chr18:47,500,320...47,577,819
Ensembl chr18:47,500,330...47,577,819
|
|
G |
Lrp5 |
LDL receptor related protein 5 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of LRP5 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 1:218,816,833...218,920,147
Ensembl chr 1:218,816,841...218,920,094
|
|
G |
Ltbp2 |
latent transforming growth factor beta binding protein 2 |
affects response to substance |
ISO |
LTBP2 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 6:108,500,114...108,596,653
Ensembl chr 6:108,500,112...108,596,569
|
|
G |
Lum |
lumican |
multiple interactions decreases response to substance |
ISO |
[Cisplatin co-treated with Paclitaxel] affects the expression of LUM mRNA LUM mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:20705681 PMID:25199881 |
|
NCBI chr 7:38,820,058...38,826,862
Ensembl chr 7:38,819,771...38,826,862
|
|
G |
Ly6c |
Ly6-C antigen |
increases expression |
EXP |
Paclitaxel results in increased expression of LY6C mRNA |
CTD |
PMID:15585946 |
|
|
|
G |
Mad2l1 |
mitotic arrest deficient 2 like 1 |
affects response to substance decreases expression |
ISO |
MAD2L1 protein affects the susceptibility to Paclitaxel Paclitaxel results in decreased expression of MAD2L1 mRNA |
CTD |
PMID:12929121 PMID:18691855 |
|
NCBI chr 4:97,530,993...97,543,179
Ensembl chr 4:97,531,083...97,537,086
|
|
G |
Madd |
MAP-kinase activating death domain |
decreases expression |
ISO |
Paclitaxel results in decreased expression of MADD mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 3:79,960,301...80,003,023
Ensembl chr 3:79,960,301...80,003,032
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
Paclitaxel results in increased expression of MAP1LC3B mRNA; Paclitaxel results in increased expression of MAP1LC3B protein |
CTD |
PMID:19815708 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]; [MAP2K1 protein affects the activity of [MAPK1 protein co-treated with MAPK3 protein]] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]; [Tretinoin co-treated with Paclitaxel] results in decreased expression of MAP2K1 protein |
CTD |
PMID:18098270 PMID:18594523 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of MAP2K3 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr10:45,089,455...45,110,802
Ensembl chr10:47,182,433...47,203,753
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
multiple interactions |
ISO |
MAP2K4 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; MAP2K4 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] |
CTD |
PMID:10075725 |
|
NCBI chr10:52,196,121...52,301,887
Ensembl chr10:52,196,124...52,290,657
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
multiple interactions increases cleavage affects localization |
ISO |
aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Paclitaxel results in increased cleavage of MAP3K1 protein]; MAP3K1 protein affects the reaction [Paclitaxel results in increased activity of MAPK8 protein]; MAP3K1 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Paclitaxel promotes the reaction [MAPK8 protein binds to MAP3K1 protein modified form] Paclitaxel affects the localization of MAP3K1 protein |
CTD |
PMID:11160861 |
|
NCBI chr 2:43,329,516...43,393,203
Ensembl chr 2:43,329,516...43,393,207
|
|
G |
Map3k2 |
mitogen activated protein kinase kinase kinase 2 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of MAP3K2 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr18:24,961,250...25,025,488
Ensembl chr18:24,961,245...25,025,897
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
MAP3K5 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; MAP3K5 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] |
CTD |
PMID:10075725 |
|
NCBI chr 1:15,412,603...15,613,752
Ensembl chr 1:15,412,603...15,613,746
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of MAP3K7 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 5:47,183,142...47,244,424
Ensembl chr 5:47,186,558...47,244,416
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation decreases phosphorylation increases activity decreases activity |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein]; 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK1 protein]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein]; [esculetin co-treated with Paclitaxel] results in decreased expression of MAPK1 protein; [MAP2K1 protein affects the activity of [MAPK1 protein co-treated with MAPK3 protein]] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]; [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; Nicotine inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein]; Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; Paclitaxel results in increased phosphorylation of and results in increased activity of MAPK1 protein; Paclitaxel results in increased phosphorylation of and results in increased expression of MAPK1 protein; SOD2 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein] CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein] Paclitaxel results in decreased phosphorylation of MAPK1 protein Paclitaxel results in decreased activity of MAPK1 protein |
CTD |
PMID:11123339 PMID:12510025 PMID:15907805 PMID:16051289 PMID:16211241 PMID:16413505 PMID:16580691 PMID:18594523 PMID:19815708 PMID:20106947 PMID:23956100 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk13 |
mitogen activated protein kinase 13 |
increases expression |
ISO |
Paclitaxel results in increased expression of MAPK13 protein |
CTD |
PMID:15907983 |
|
NCBI chr20:6,018,374...6,027,467
Ensembl chr20:6,018,374...6,027,473
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
[esculetin co-treated with Paclitaxel] results in decreased expression of MAPK14 protein; [Paclitaxel co-treated with Metformin] results in decreased expression of MAPK14 mRNA |
CTD |
PMID:16051289 PMID:29309887 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation increases activity decreases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein]; 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein]; [esculetin co-treated with Paclitaxel] results in decreased expression of MAPK3 protein; [MAP2K1 protein affects the activity of [MAPK1 protein co-treated with MAPK3 protein]] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel]; [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; [Tretinoin co-treated with Paclitaxel] results in increased phosphorylation of MAPK3 protein; Nicotine inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein]; Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; Paclitaxel results in increased phosphorylation of and results in increased activity of MAPK3 protein; Paclitaxel results in increased phosphorylation of and results in increased expression of MAPK3 protein; SOD2 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein] CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein] Paclitaxel results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:11123339 PMID:12510025 PMID:15907805 PMID:16051289 PMID:16211241 PMID:16413505 PMID:16580691 PMID:18098270 PMID:18594523 PMID:20106947 PMID:23956100 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation increases expression increases activity |
ISO |
[esculetin co-treated with Paclitaxel] results in increased expression of MAPK8 protein; [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein; aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Paclitaxel results in increased activity of MAPK8 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein]; MAP3K1 protein affects the reaction [Paclitaxel results in increased activity of MAPK8 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Paclitaxel promotes the reaction [MAPK8 protein binds to MAP3K1 protein modified form] Paclitaxel results in increased phosphorylation of MAPK8 protein CD14 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK8 protein]; ITGAM protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK8 protein] Paclitaxel results in increased expression of MAPK8 protein |
CTD |
PMID:10075725 PMID:11123339 PMID:11160861 PMID:16051289 PMID:19426673 PMID:19944065 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions increases expression |
ISO EXP |
[esculetin co-treated with Paclitaxel] results in increased expression of MAPK9 protein; [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein] Paclitaxel results in increased expression of MAPK9 protein Paclitaxel analog results in increased expression of MAPK9 mRNA |
CTD |
PMID:15585946 PMID:16051289 PMID:19944065 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mapkapk5 |
MAPK activated protein kinase 5 |
affects response to substance |
ISO |
MAPKAPK5 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr12:40,510,378...40,529,332
Ensembl chr12:40,510,378...40,529,338
|
|
G |
Mapre1 |
microtubule-associated protein, RP/EB family, member 1 |
multiple interactions decreases localization |
ISO |
olesoxime inhibits the reaction [Paclitaxel results in decreased localization of MAPRE1 protein] |
CTD |
PMID:20417191 |
|
NCBI chr 3:149,221,346...149,249,469
Ensembl chr 3:149,221,377...149,249,273
|
|
G |
Mapre3 |
microtubule-associated protein, RP/EB family, member 3 |
affects localization multiple interactions |
ISO |
Paclitaxel affects the localization of MAPRE3 protein olesoxime inhibits the reaction [Paclitaxel results in decreased localization of MAPRE3 protein] |
CTD |
PMID:20417191 |
|
NCBI chr 6:26,878,738...26,923,459
Ensembl chr 6:26,878,744...26,889,882
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions decreases expression |
ISO EXP |
MAPT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] Paclitaxel inhibits the reaction [annonacin affects the localization of MAPT protein] Paclitaxel results in decreased expression of MAPT mRNA; Paclitaxel results in decreased expression of MAPT protein |
CTD |
PMID:16896004 PMID:16930453 PMID:17634376 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Marveld1 |
MARVEL domain containing 1 |
increases response to substance |
ISO |
MARVELD1 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:27447558 |
|
NCBI chr 1:261,389,804...261,393,736
Ensembl chr 1:261,389,804...261,393,736
|
|
G |
Matk |
megakaryocyte-associated tyrosine kinase |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of MATK mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 7:11,325,246...11,334,311
Ensembl chr 7:11,325,254...11,330,278
|
|
G |
Matn2 |
matrilin 2 |
multiple interactions decreases response to substance |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of MATN2 mRNA MATN2 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:20705681 PMID:25199881 |
|
NCBI chr 7:72,985,832...73,210,093
Ensembl chr 7:72,985,495...73,207,695
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Paclitaxel results in decreased expression of MCL1 protein |
CTD |
PMID:14749477 |
|
NCBI chr 2:197,786,212...197,788,992
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
decreases response to substance |
ISO |
MDM2 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:13130078 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Med1 |
mediator complex subunit 1 |
multiple interactions |
ISO |
Paclitaxel promotes the reaction [NR1I2 protein binds to MED1 protein] |
CTD |
PMID:15650019 |
|
NCBI chr10:86,101,560...86,145,271
Ensembl chr10:86,103,600...86,144,880
|
|
G |
Med13l |
mediator complex subunit 13L |
multiple interactions |
ISO |
MED13L mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr12:43,421,317...43,576,859
Ensembl chr12:43,421,308...43,576,804
|
|
G |
Med4 |
mediator complex subunit 4 |
affects response to substance |
ISO |
MED4 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr15:55,406,543...55,416,816
Ensembl chr15:55,406,543...55,416,815
|
|
G |
Melk |
maternal embryonic leucine zipper kinase |
multiple interactions |
ISO |
MELK mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 5:59,783,835...59,844,356
Ensembl chr 5:59,783,890...59,844,356
|
|
G |
Men1 |
menin 1 |
increases expression |
EXP |
Paclitaxel results in increased expression of MEN1 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 1:221,704,394...221,710,343
Ensembl chr 1:221,704,493...221,710,331
|
|
G |
Metrn |
meteorin, glial cell differentiation regulator |
multiple interactions |
ISO |
METRN mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:15,164,439...15,166,457
Ensembl chr10:15,164,439...15,166,457
|
|
G |
Mfap5 |
microfibril associated protein 5 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of MFAP5 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 4:155,313,671...155,336,228
Ensembl chr 4:155,313,671...155,336,228
|
|
G |
Mfn2 |
mitofusin 2 |
decreases expression |
EXP |
Paclitaxel results in decreased expression of MFN2 mRNA |
CTD |
PMID:28587902 |
|
NCBI chr 5:164,684,244...164,715,414
Ensembl chr 5:164,684,509...164,714,145
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
increases expression |
ISO |
Paclitaxel results in increased expression of MGMT mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Micb |
MHC class I polypeptide-related sequence B |
increases response to substance |
ISO |
MICB protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 1:79,754,587...79,772,092
Ensembl chr 1:79,754,587...79,772,092
|
|
G |
Mir874 |
microRNA 874 |
increases response to substance |
ISO |
MIR874 mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:30004169 |
|
NCBI chr17:7,025,014...7,025,089
Ensembl chr17:7,025,014...7,025,089
|
|
G |
Mlec |
malectin |
affects response to substance |
ISO |
MLEC protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr12:47,219,071...47,233,769
Ensembl chr12:47,218,969...47,252,286
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
affects response to substance multiple interactions |
ISO |
MMP1 protein affects the susceptibility to Paclitaxel [Cisplatin co-treated with Paclitaxel] results in decreased expression of MMP1 mRNA |
CTD |
PMID:16217747 PMID:20705681 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of MMP10 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 8:5,734,348...5,742,243
Ensembl chr 8:5,734,348...5,742,243
|
|
G |
Mmp16 |
matrix metallopeptidase 16 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of MMP16 mRNA |
CTD |
PMID:18058816 |
|
NCBI chr 5:31,568,344...31,818,368
Ensembl chr 5:31,568,419...31,810,484
|
|
G |
Mmp17 |
matrix metallopeptidase 17 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of MMP17 mRNA |
CTD |
PMID:18058816 |
|
NCBI chr12:30,353,874...30,356,526 NCBI chr12:30,701,900...30,728,683
Ensembl chr12:30,702,571...30,728,655
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of MMP2 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression multiple interactions |
EXP ISO |
Paclitaxel results in increased expression of MMP3; Paclitaxel results in increased expression of MMP3 mRNA [Cisplatin co-treated with Paclitaxel] results in increased expression of MMP3 mRNA |
CTD |
PMID:18754875 PMID:20705681 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of MMP9 mRNA; Curcumin inhibits the reaction [Paclitaxel results in increased expression of MMP9 protein] |
CTD |
PMID:16243823 PMID:20705681 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mok |
MOK protein kinase |
affects response to substance |
ISO |
MOK protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 6:135,228,755...135,259,645
Ensembl chr 6:135,228,803...135,259,603
|
|
G |
Mphosph6 |
M phase phosphoprotein 6 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of MPHOSPH6 protein |
CTD |
PMID:15907983 |
|
NCBI chr19:50,357,314...50,367,137
Ensembl chr19:50,357,338...50,367,187
|
|
G |
Mpp3 |
membrane palmitoylated protein 3 |
increases expression |
ISO |
Paclitaxel results in increased expression of MPP3 protein |
CTD |
PMID:15907983 |
|
NCBI chr10:89,930,270...89,959,462
Ensembl chr10:89,930,241...89,959,176
|
|
G |
Mpzl2 |
myelin protein zero-like 2 |
decreases expression increases expression |
ISO EXP |
Paclitaxel results in decreased expression of MPZL2 mRNA Paclitaxel results in increased expression of MPZL2 mRNA |
CTD |
PMID:18754875 PMID:19682730 |
|
NCBI chr 8:49,342,067...49,353,080
Ensembl chr 8:49,342,067...49,353,080
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
increases expression |
EXP |
Paclitaxel results in increased expression of MRC1 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr17:81,352,700...81,433,743
Ensembl chr17:81,352,700...81,433,743
|
|
G |
Mrpl40 |
mitochondrial ribosomal protein L40 |
affects response to substance |
ISO |
MRPL40 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr11:86,276,616...86,282,452
Ensembl chr11:86,276,616...86,282,451
|
|
G |
Mrpl57 |
mitochondrial ribosomal protein L57 |
affects response to substance |
ISO |
MRPL57 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr15:38,096,994...38,097,856
Ensembl chr15:38,095,803...38,097,835
|
|
G |
Mrps15 |
mitochondrial ribosomal protein S15 |
affects response to substance |
ISO |
MRPS15 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 5:144,054,452...144,065,045
Ensembl chr 5:144,054,452...144,065,045
|
|
G |
Mrps18b |
mitochondrial ribosomal protein S18B |
decreases expression |
ISO |
Paclitaxel results in decreased expression of MRPS18B protein |
CTD |
PMID:15907983 |
|
NCBI chr20:3,344,870...3,350,929
Ensembl chr20:3,344,870...3,350,927
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
affects response to substance |
ISO |
MSMO1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr16:26,859,441...26,875,880
Ensembl chr16:26,859,397...26,875,973
|
|
G |
Mt2A |
metallothionein 2A |
increases response to substance |
ISO |
MT2A mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
ISO |
Paclitaxel results in increased phosphorylation of MTOR protein |
CTD |
PMID:27769712 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Muc16 |
mucin 16, cell surface associated |
multiple interactions decreases expression |
ISO |
[Paclitaxel co-treated with Cisplatin] results in decreased expression of MUC16 protein Paclitaxel results in decreased expression of MUC16 protein |
CTD |
PMID:8751544 PMID:11706781 |
|
NCBI chr 8:18,438,838...18,639,777
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions affects response to substance decreases expression |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of MYC mRNA; [Paclitaxel co-treated with Metformin] results in decreased expression of MYC mRNA; Curcumin inhibits the reaction [Paclitaxel results in increased expression of MYC protein] MYC protein affects the susceptibility to Paclitaxel Paclitaxel results in decreased expression of MYC protein |
CTD |
PMID:15907983 PMID:16243823 PMID:18802399 PMID:20705681 PMID:29309887 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Myo5a |
myosin VA |
increases response to substance |
ISO |
MYO5A protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 8:82,038,966...82,156,507
Ensembl chr 8:82,037,977...82,156,617
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions decreases expression |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of NAMPT mRNA Paclitaxel results in decreased expression of NAMPT mRNA |
CTD |
PMID:12929121 PMID:20705681 |
|
NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
|
|
G |
Nanog |
Nanog homeobox |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of NANOG mRNA; [Cisplatin co-treated with Paclitaxel] results in increased expression of NANOG protein |
CTD |
PMID:20705681 |
|
NCBI chr 4:155,531,906...155,539,268
Ensembl chr 4:155,531,906...155,539,268
|
|
G |
Nat1 |
N-acetyltransferase 1 |
decreases activity decreases expression |
ISO |
Paclitaxel results in decreased activity of NAT1 mRNA; Paclitaxel results in decreased activity of NAT1 protein Paclitaxel results in decreased expression of NAT1 mRNA |
CTD |
PMID:15015580 PMID:17564303 |
|
NCBI chr16:23,970,742...23,991,573
Ensembl chr16:23,970,743...23,991,573
|
|
G |
Nav3 |
neuron navigator 3 |
affects response to substance |
ISO |
NAV3 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 7:52,164,805...52,508,145
Ensembl chr 7:52,165,233...52,404,774
|
|
G |
Ncapg |
non-SMC condensin I complex, subunit G |
affects response to substance |
ISO |
NCAPG protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr14:69,898,268...69,927,885
Ensembl chr14:69,899,128...69,927,938
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
Ketoconazole inhibits the reaction [Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA1 protein] |
CTD |
PMID:16819505 |
|
NCBI chr 6:28,677,563...28,931,844
Ensembl chr 6:28,677,540...28,931,843
|
|
G |
Ncoa3 |
nuclear receptor coactivator 3 |
multiple interactions |
ISO |
Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA3 protein] |
CTD |
PMID:15650019 |
|
NCBI chr 3:162,692,176...162,788,582
Ensembl chr 3:162,692,185...162,787,548
|
|
G |
Ndufa1 |
NADH:ubiquinone oxidoreductase subunit A1 |
affects response to substance |
ISO |
NDUFA1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr X:123,803,109...123,806,760
Ensembl chr X:124,513,269...124,516,705 Ensembl chr X:124,513,269...124,516,705
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
affects response to substance |
ISO |
NDUFA13 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr16:21,275,311...21,282,246
Ensembl chr16:21,275,311...21,282,246
|
|
G |
Ndufa3 |
NADH:ubiquinone oxidoreductase subunit A3 |
affects response to substance |
ISO |
NDUFA3 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 1:64,172,462...64,175,174
Ensembl chr 1:64,172,540...64,175,099
|
|
G |
Ndufb2 |
NADH:ubiquinone oxidoreductase subunit B2 |
affects response to substance |
ISO |
NDUFB2 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 4:67,378,188...67,385,267
Ensembl chr 4:67,378,188...67,385,266
|
|
G |
Ndufb7 |
NADH:ubiquinone oxidoreductase subunit B7 |
affects response to substance |
ISO |
NDUFB7 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr19:24,701,067...24,705,405
Ensembl chr19:24,701,049...24,705,405
|
|
G |
Ndufs4 |
NADH:ubiquinone oxidoreductase subunit S4 |
multiple interactions |
ISO |
Paclitaxel inhibits the reaction [NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Dopamine]]; Paclitaxel inhibits the reaction [NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Reactive Oxygen Species]] |
CTD |
PMID:21383081 |
|
NCBI chr 2:46,372,488...46,476,162
Ensembl chr 2:46,372,518...46,476,203
|
|
G |
Ndufs8 |
NADH:ubiquinone oxidoreductase core subunit S8 |
affects response to substance |
ISO |
NDUFS8 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 1:219,141,289...219,144,610
Ensembl chr 1:219,141,292...219,144,610
|
|
G |
Ndufv1 |
NADH:ubiquinone oxidoreductase core subunit V1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of NDUFV1 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 1:219,254,293...219,259,328
Ensembl chr 1:219,254,279...219,259,448
|
|
G |
Nes |
nestin |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of NES mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 2:187,343,109...187,352,972
Ensembl chr 2:187,344,056...187,352,969
|
|
G |
Neurod4 |
neuronal differentiation 4 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of NEUROD4 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 7:9,699,964...9,712,067
Ensembl chr 7:9,699,961...9,711,928
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
decreases response to substance multiple interactions decreases expression |
ISO EXP |
NFE2L2 results in decreased susceptibility to Paclitaxel [KEAP1 protein results in decreased stability of NFE2L2 protein] which results in increased susceptibility to Paclitaxel Paclitaxel results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:15585946 PMID:20530669 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
ITGAM protein affects the reaction [Paclitaxel affects the localization of and results in increased activity of [NFKB1 protein binds to RELA protein]]; Paclitaxel affects the localization of and results in increased activity of [NFKB1 protein binds to RELA protein] [Paclitaxel co-treated with Metformin] results in decreased expression of NFKB1 mRNA; Curcumin inhibits the reaction [Paclitaxel results in increased activity of NFKB1 protein] |
CTD |
PMID:11123339 PMID:16243823 PMID:29309887 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of NFKB2 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 1:266,050,634...266,059,277
Ensembl chr 1:266,053,002...266,059,256
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Paclitaxel results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:16243823 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Ngf |
nerve growth factor |
decreases response to substance multiple interactions decreases expression |
EXP |
NGF protein results in decreased susceptibility to Paclitaxel Tretinoin inhibits the reaction [Paclitaxel results in decreased expression of NGF protein] |
CTD |
PMID:9622663 PMID:10553948 PMID:21865574 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Nkain1 |
Sodium/potassium transporting ATPase interacting 1 |
multiple interactions |
ISO |
NKAIN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 5:148,635,537...148,669,709
Ensembl chr 5:148,661,070...148,667,746
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
increases expression |
EXP |
Paclitaxel results in increased expression of NME1 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr10:81,657,152...81,666,542
Ensembl chr10:81,657,153...81,666,523
|
|
G |
Nme4 |
NME/NM23 nucleoside diphosphate kinase 4 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of NME4 protein |
CTD |
PMID:15907983 |
|
NCBI chr10:15,461,567...15,465,422
Ensembl chr10:15,431,638...15,465,413
|
|
G |
Nmrk2 |
nicotinamide riboside kinase 2 |
decreases response to substance |
ISO |
ITGB1BP3 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:25199881 |
|
NCBI chr 7:11,382,966...11,386,170
Ensembl chr 7:11,383,116...11,386,948
|
|
G |
Nod1 |
nucleotide-binding oligomerization domain containing 1 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of NOD1 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 4:85,123,965...85,175,206
Ensembl chr 4:85,123,960...85,174,951
|
|
G |
Nop58 |
NOP58 ribonucleoprotein |
decreases expression |
ISO |
Paclitaxel results in decreased expression of NOL5 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 9:66,495,881...66,520,521
Ensembl chr 9:66,495,832...66,519,788
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases expression multiple interactions |
ISO |
Paclitaxel results in decreased expression of NOS3 mRNA; Paclitaxel results in decreased expression of NOS3 protein Aspirin inhibits the reaction [Paclitaxel results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Paclitaxel results in decreased expression of NOS3 protein] |
CTD |
PMID:19520256 PMID:19815708 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Npm1 |
nucleophosmin 1 |
decreases response to substance |
ISO |
NPM1 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:24736981 |
|
NCBI chr10:18,080,949...18,091,062
Ensembl chr10:18,080,950...18,090,950
|
|
G |
Npy |
neuropeptide Y |
increases expression |
EXP |
Paclitaxel results in increased expression of NPY protein |
CTD |
PMID:17686523 |
|
NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity increases abundance multiple interactions |
ISO |
Paclitaxel results in increased activity of NR1I2 protein NR1I2 gene mutant form results in increased abundance of Paclitaxel [Paclitaxel results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; [SR 12813 results in increased activity of NR1I2 protein] which results in decreased susceptibility to Paclitaxel; Ketoconazole inhibits the reaction [Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Paclitaxel results in increased activity of NR1I2 protein]; NR1I2 protein promotes the reaction [Paclitaxel results in increased expression of and results in increased activity of ABCB1 protein]; Paclitaxel binds to and results in increased activity of NR1I2 protein; Paclitaxel promotes the reaction [NR1I2 protein binds to MED1 protein]; Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA3 protein] |
CTD |
PMID:12065438 PMID:14977870 PMID:15650019 PMID:15864135 PMID:16819505 PMID:17438109 PMID:18839173 PMID:19746521 PMID:20041327 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of NRAS mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 2:205,553,119...205,563,716
Ensembl chr 2:205,553,163...205,560,791
|
|
G |
Nrp1 |
neuropilin 1 |
increases expression |
ISO |
Paclitaxel results in increased expression of NRP1 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr19:61,332,351...61,486,166
Ensembl chr19:61,332,351...61,485,858
|
|
G |
Nudt12 |
nudix hydrolase 12 |
increases expression |
ISO |
Paclitaxel results in increased expression of NUDT12 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 9:105,680,603...105,693,374
Ensembl chr 9:105,680,670...105,693,357
|
|
G |
Nudt15 |
nudix hydrolase 15 |
affects response to substance |
ISO |
NUDT15 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr15:55,417,774...55,456,698
Ensembl chr15:55,419,502...55,456,698
|
|
G |
Nudt4 |
nudix hydrolase 4 |
affects response to substance |
ISO |
NUDT4 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 7:36,643,916...36,660,334
Ensembl chr 7:36,643,916...36,660,141
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
EXP |
Paclitaxel results in increased expression of NUPR1 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
|
|
G |
Nus1 |
NUS1 dehydrodolichyl diphosphate synthase subunit |
decreases expression |
ISO |
Paclitaxel results in decreased expression of NUS1 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr20:33,557,052...33,584,011
Ensembl chr20:33,557,052...33,584,010
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
affects response to substance |
ISO |
NUSAP1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 3:111,422,267...111,452,600
Ensembl chr 3:111,422,267...111,452,971
|
|
G |
Oat |
ornithine aminotransferase |
increases expression |
EXP |
Paclitaxel analog results in increased expression of OAT mRNA; Paclitaxel results in increased expression of OAT mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 1:204,562,289...204,582,070
Ensembl chr 1:204,562,289...204,582,070
|
|
G |
Obp3 |
alpha-2u globulin PGCL4 |
increases expression |
EXP |
Paclitaxel results in increased expression of OBP3 mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 5:77,313,357...77,316,875
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
increases expression |
ISO |
Paclitaxel results in increased expression of OGG1 protein |
CTD |
PMID:15907983 |
|
NCBI chr 4:145,282,828...145,289,367
Ensembl chr 4:145,282,797...145,289,326
|
|
G |
Ogn |
osteoglycin |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of OGN mRNA |
CTD |
PMID:20705681 |
|
NCBI chr17:14,607,442...14,628,274
Ensembl chr17:15,447,716...15,467,359 Ensembl chr17:15,447,716...15,467,359
|
|
G |
Olfml3 |
olfactomedin-like 3 |
increases expression |
ISO |
Paclitaxel results in increased expression of OLFML3 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr 2:206,219,419...206,222,248
Ensembl chr 2:206,219,419...206,222,248
|
|
G |
Osbpl10 |
oxysterol binding protein-like 10 |
affects response to substance |
ISO |
OSBPL10 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 8:123,029,722...123,303,553
Ensembl chr 8:123,126,667...123,293,562
|
|
G |
Osmr |
oncostatin M receptor |
increases response to substance |
ISO |
OSMR protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 2:56,107,491...56,163,522
Ensembl chr 2:56,110,777...56,151,531
|
|
G |
Osr2 |
odd-skipped related transciption factor 2 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of OSR2 mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 7:74,047,820...74,055,096
Ensembl chr 7:74,047,814...74,055,256
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
increases expression |
EXP |
Paclitaxel analog results in increased expression of OXT mRNA; Paclitaxel results in increased expression of OXT mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 3:123,106,694...123,107,534
Ensembl chr 3:123,106,694...123,107,534
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
increases expression multiple interactions |
EXP |
Paclitaxel results in increased expression of P2RX4 protein 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine inhibits the reaction [Paclitaxel results in increased expression of P2RX4 protein] |
CTD |
PMID:30414958 |
|
NCBI chr12:39,308,022...39,325,673
Ensembl chr12:39,308,025...39,325,673
|
|
G |
Padi2 |
peptidyl arginine deiminase 2 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of PADI2 protein |
CTD |
PMID:15907983 |
|
NCBI chr 5:159,428,479...159,471,113
Ensembl chr 5:159,428,515...159,471,144
|
|
G |
Papln |
papilin, proteoglycan-like sulfated glycoprotein |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in decreased expression of PAPLN mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 6:107,245,573...107,282,256
Ensembl chr 6:107,245,820...107,276,755
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage affects response to substance multiple interactions |
ISO |
Paclitaxel results in increased cleavage of PARP1 protein PARP1 protein affects the susceptibility to Paclitaxel [3,3'-diindolylmethane co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of PARP1 protein; [Luteolin co-treated with Paclitaxel] results in decreased expression of PARP1 protein; [resveratrol co-treated with Paclitaxel] results in increased cleavage of PARP1 protein; AKT1 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; alvocidib promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; CD40LG protein inhibits the reaction [Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; MAP2K4 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; MAP3K5 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; MAPK8 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; TYMP inhibits the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; TYMP mutant form promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein] |
CTD |
PMID:10075725 PMID:10430095 PMID:10502406 PMID:11774260 PMID:14749477 PMID:15492279 PMID:15585644 PMID:15907805 PMID:16545138 PMID:16580691 PMID:17404021 PMID:18071906 PMID:18451153 PMID:19426673 PMID:20610805 PMID:24126434 PMID:24525192 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pawr |
pro-apoptotic WT1 regulator |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of PAWR mRNA |
CTD |
PMID:20705681 |
|
NCBI chr 7:51,273,764...51,353,700
Ensembl chr 7:51,273,771...51,353,068
|
|
G |
Pcca |
propionyl-CoA carboxylase subunit alpha |
decreases expression |
ISO |
Paclitaxel results in decreased expression of PCCA protein |
CTD |
PMID:15907983 |
|
NCBI chr15:108,960,509...109,306,879
Ensembl chr15:108,960,562...109,306,603
|
|
G |
Pccb |
propionyl-CoA carboxylase subunit beta |
increases expression |
EXP |
Paclitaxel results in increased expression of PCCB mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 8:109,368,887...109,418,871
Ensembl chr 8:109,368,624...109,418,872
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions increases expression |
ISO |
[Imatinib Mesylate co-treated with Paclitaxel] results in decreased expression of PCNA protein Paclitaxel results in increased expression of PCNA |
CTD |
PMID:9858906 PMID:15867366 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pcolce |
procollagen C-endopeptidase enhancer |
increases expression |
ISO |
Paclitaxel results in increased expression of PCOLCE mRNA |
CTD |
PMID:19682730 |
|
NCBI chr12:22,153,995...22,160,311
Ensembl chr12:22,153,983...22,160,337
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
[PDK1 protein binds to AKT1 protein] results in decreased susceptibility to [Paclitaxel co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]; [PDK1 protein binds to AKT1 protein] which results in decreased susceptibility to Paclitaxel |
CTD |
PMID:20361045 |
|
NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
decreases response to substance |
ISO |
PDPK1 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16782806 |
|
NCBI chr10:13,446,373...13,525,248
Ensembl chr10:13,451,624...13,515,448
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
multiple interactions |
ISO |
[Imatinib Mesylate co-treated with Paclitaxel] results in decreased expression of PECAM1 protein; zoledronic acid promotes the reaction [[Imatinib Mesylate co-treated with Paclitaxel] results in decreased expression of PECAM1 protein] |
CTD |
PMID:15867366 |
|
NCBI chr10:94,850,971...94,913,202
|
|
G |
Perp |
p53 apoptosis effector related to PMP22 |
increases expression |
ISO |
Paclitaxel results in increased expression of PERP mRNA |
CTD |
PMID:18058816 |
|
NCBI chr 1:14,224,392...14,236,838
Ensembl chr 1:14,224,393...14,236,846
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
decreases expression |
EXP |
Paclitaxel results in decreased expression of PHGDH protein |
CTD |
PMID:21118710 |
|
NCBI chr 2:200,484,245...200,513,564
Ensembl chr 2:200,484,246...200,513,564
|
|
G |
Pik3c2a |
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha |
affects response to substance |
ISO |
PIK3C2A protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 1:185,210,922...185,326,314
Ensembl chr 1:185,210,922...185,326,314
|
|
G |
Pkd2 |
polycystin 2, transient receptor potential cation channel |
increases response to substance |
ISO |
PKD2 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr14:6,602,004...6,645,257
Ensembl chr14:6,602,004...6,645,257
|
|
G |
Pklr |
pyruvate kinase L/R |
decreases expression |
ISO |
Paclitaxel results in decreased expression of PKLR mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 2:188,449,158...188,458,034
Ensembl chr 2:188,449,210...188,459,592
|
|
G |
Pkm |
pyruvate kinase M1/2 |
affects response to substance |
ISO |
PKM protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
|
|
G |
Pkp2 |
plakophilin 2 |
decreases response to substance |
ISO |
PKP2 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr11:88,912,163...88,972,213
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
increases expression |
EXP |
Paclitaxel results in increased expression of PLA2G2A mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 5:157,282,650...157,285,295
Ensembl chr 5:157,282,669...157,285,328
|
|
G |
Pla2g2d |
phospholipase A2, group IID |
increases expression |
EXP |
Paclitaxel results in increased expression of PLA2G2D mRNA |
CTD |
PMID:18754875 |
|
NCBI chr 5:157,222,636...157,228,795
Ensembl chr 5:157,222,636...157,228,791
|
|
G |
Plce1 |
phospholipase C, epsilon 1 |
decreases response to substance |
ISO |
PLCE1 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 1:257,156,023...257,465,440
Ensembl chr 1:257,157,264...257,466,064
|
|
G |
Plcl1 |
phospholipase C-like 1 |
increases expression |
EXP |
Paclitaxel analog results in increased expression of PLCL1 mRNA; Paclitaxel results in increased expression of PLCL1 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 9:62,016,112...62,349,244
Ensembl chr 9:62,291,405...62,349,309
|
|
G |
Plk1 |
polo-like kinase 1 |
multiple interactions |
ISO |
[pifithrin co-treated with Paclitaxel] results in increased expression of PLK1 protein |
CTD |
PMID:18516295 |
|
NCBI chr 1:192,115,990...192,125,969
Ensembl chr 1:192,115,966...192,125,989
|
|
G |
Plk4 |
polo-like kinase 4 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of PLK4 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 2:127,686,911...127,705,518
Ensembl chr 2:127,686,925...127,705,518
|
|
G |
Plpp1 |
phospholipid phosphatase 1 |
decreases response to substance |
ISO |
PLPP1 protein results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 2:44,664,076...44,726,820
Ensembl chr 2:44,664,124...44,726,689
|
|
G |
Plpp2 |
phospholipid phosphatase 2 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of PLPP2 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr 7:13,062,168...13,070,281
Ensembl chr 7:13,062,196...13,070,280
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
decreases response to substance |
ISO |
PMP22 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
|
|
G |
Polk |
DNA polymerase kappa |
decreases expression |
ISO |
Paclitaxel results in decreased expression of POLK mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 2:27,305,718...27,364,906
Ensembl chr 2:27,305,728...27,364,906
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases response to substance |
ISO |
POR mRNA results in increased susceptibility to Paclitaxel |
CTD |
PMID:15239142 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Postn |
periostin |
decreases response to substance increases expression |
ISO |
POSTN mRNA results in decreased susceptibility to Paclitaxel Paclitaxel results in increased expression of POSTN mRNA |
CTD |
PMID:19682730 PMID:25199881 |
|
NCBI chr 2:143,656,820...143,688,087
Ensembl chr 2:143,656,793...143,688,087
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of POU5F1 mRNA; [Cisplatin co-treated with Paclitaxel] results in increased expression of POU5F1 protein |
CTD |
PMID:20705681 |
|
NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
|
|
G |
Ppib |
peptidylprolyl isomerase B |
affects response to substance |
ISO |
PPIB protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 8:71,719,681...71,725,538
Ensembl chr 8:71,719,563...71,725,562
|
|
G |
Ppp1cb |
protein phosphatase 1 catalytic subunit beta |
affects response to substance |
ISO |
PPP1CB protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 6:23,548,507...23,581,136
Ensembl chr 6:23,549,317...23,581,052
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
decreases expression |
ISO |
Paclitaxel results in decreased expression of PPP1R12A mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 7:51,404,971...51,515,382
Ensembl chr 7:51,404,919...51,515,373
|
|
G |
Ppp1r9a |
protein phosphatase 1, regulatory subunit 9A |
decreases expression |
ISO |
Paclitaxel results in decreased expression of PPP1R9A mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 4:29,976,485...30,247,371
Ensembl chr 4:29,978,739...30,241,911
|
|
G |
Ppt1 |
palmitoyl-protein thioesterase 1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of PPT1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 5:140,538,260...140,558,163
Ensembl chr 5:140,538,260...140,558,162
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
increases expression |
ISO |
Paclitaxel results in increased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:142,087,181...142,108,746
Ensembl chr 1:142,087,208...142,108,746
|
|
G |
Prdm1 |
PR/SET domain 1 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in increased expression of PRDM1 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr20:49,464,921...49,556,623
Ensembl chr20:49,464,919...49,556,518
|
|
G |
Prdm4 |
PR/SET domain 4 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of PRDM4 protein |
CTD |
PMID:15907983 |
|
NCBI chr 7:23,959,932...23,986,535
Ensembl chr 7:23,960,378...23,985,525
|
|
G |
Prdx2 |
peroxiredoxin 2 |
affects response to substance |
ISO |
PRDX2 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr19:26,084,816...26,090,095
Ensembl chr19:26,084,903...26,090,094
|
|
G |
Prkcd |
protein kinase C, delta |
affects localization |
ISO |
Paclitaxel affects the localization of PRKCD protein |
CTD |
PMID:9852137 |
|
NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
|
|
G |
Prkce |
protein kinase C, epsilon |
affects response to substance |
EXP |
PRKCE protein affects the susceptibility to Paclitaxel |
CTD |
PMID:11738263 |
|
NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
|
|
G |
Prom1 |
prominin 1 |
multiple interactions decreases response to substance |
ISO |
[Cisplatin co-treated with Paclitaxel] results in increased expression of PROM1 mRNA PROM1 results in decreased susceptibility to Paclitaxel |
CTD |
PMID:20705681 PMID:21919130 |
|
NCBI chr14:71,532,321...71,637,400
Ensembl chr14:71,533,063...71,637,417
|
|
G |
Prrg4 |
proline rich and Gla domain 4 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of PRRG4 mRNA |
CTD |
PMID:19682730 |
|
NCBI chr 3:94,783,866...94,808,861
Ensembl chr 3:94,784,008...94,808,861
|
|
G |
Psap |
prosaposin |
decreases expression |
ISO |
Paclitaxel results in decreased expression of PSAP mRNA |
CTD |
PMID:15000894 |
|
NCBI chr20:29,831,302...29,856,876
Ensembl chr20:29,831,314...29,856,875
|
|
G |
Psma4 |
proteasome 20S subunit alpha 4 |
affects response to substance |
ISO |
PSMA4 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 8:59,532,456...59,539,916
Ensembl chr 8:59,532,389...59,539,920
|
|
G |
Psmb1 |
proteasome 20S subunit beta 1 |
affects response to substance |
ISO |
PSMB1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 1:57,470,878...57,491,359
Ensembl chr 1:57,470,632...57,489,727
|
|
G |
Psmb6 |
proteasome 20S subunit beta 6 |
affects response to substance |
ISO |
PSMB6 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr10:57,131,339...57,133,685
Ensembl chr10:57,131,386...57,133,637
|
|
G |
Pten |
phosphatase and tensin homolog |
increases response to substance increases activity |
ISO |
PTEN results in increased susceptibility to Paclitaxel Paclitaxel results in increased activity of PTEN protein |
CTD |
PMID:11707646 PMID:15548710 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
decreases expression |
EXP |
Paclitaxel results in decreased expression of PTGER4 mRNA |
CTD |
PMID:15585946 |
|
NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
|
|
G |
Ptges3 |
prostaglandin E synthase 3 |
affects response to substance |
ISO |
PTGES3 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 7:2,479,267...2,497,024
Ensembl chr 7:2,479,311...2,497,013
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression decreases expression |
ISO |
Curcumin inhibits the reaction [Paclitaxel results in increased expression of PTGS2 mRNA]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of PTGS2 protein]; PTGS2 protein results in decreased susceptibility to [Platinum co-treated with Paclitaxel] CD14 protein affects the reaction [Paclitaxel results in increased expression of PTGS2 mRNA]; ITGAM protein affects the reaction [Paclitaxel results in increased expression of PTGS2 mRNA]; TLR4 protein affects the reaction [Paclitaxel results in increased expression of PTGS2 mRNA] Paclitaxel results in decreased expression of PTGS2 protein |
CTD |
PMID:11123339 PMID:15907983 PMID:16243823 PMID:16831230 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptk6 |
protein tyrosine kinase 6 |
increases expression |
ISO |
Paclitaxel results in increased expression of PTK6 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 3:176,698,305...176,706,896
Ensembl chr 3:176,698,305...176,706,896
|
|
G |
Ptpn13 |
protein tyrosine phosphatase, non-receptor type 13 |
increases response to substance |
ISO |
PTPN13 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr14:7,688,551...7,863,664
Ensembl chr14:7,688,551...7,863,664
|
|
G |
Ptpn7 |
protein tyrosine phosphatase, non-receptor type 7 |
increases expression |
ISO |
Paclitaxel results in increased expression of PTPN7 protein |
CTD |
PMID:15907983 |
|
NCBI chr13:51,958,023...51,971,431
Ensembl chr13:51,958,834...51,972,777
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
affects expression |
ISO |
Paclitaxel affects the expression of PTTG1 protein |
CTD |
PMID:27769712 |
|
NCBI chr10:29,014,332...29,026,088
Ensembl chr10:29,020,049...29,026,002
|
|
G |
Qrich1 |
glutamine-rich 1 |
increases phosphorylation |
ISO |
Paclitaxel results in increased phosphorylation of QRICH1 protein |
CTD |
PMID:17510977 |
|
NCBI chr 8:117,305,803...117,346,738
Ensembl chr 8:117,307,339...117,346,736
|
|
G |
Qsox1 |
quiescin sulfhydryl oxidase 1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of QSOX1 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr13:73,423,396...73,460,890
Ensembl chr13:73,423,397...73,460,935
|
|
G |
Rab34 |
RAB34, member RAS oncogene family |
increases expression |
ISO |
Paclitaxel results in increased expression of RAB34 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr10:65,448,111...65,452,178
Ensembl chr10:65,448,950...65,452,177
|
|
G |
Rac1 |
Rac family small GTPase 1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of RAC1 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
|
|
G |
Rad23a |
RAD23 homolog A, nucleotide excision repair protein |
decreases expression |
ISO |
Paclitaxel results in decreased expression of RAD23A mRNA |
CTD |
PMID:12929121 |
|
NCBI chr19:25,949,488...25,956,677
Ensembl chr19:25,949,490...25,955,391
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
increases phosphorylation multiple interactions |
ISO |
Paclitaxel results in increased phosphorylation of RAF1 protein [pifithrin co-treated with Paclitaxel] results in increased phosphorylation of RAF1 protein; resveratrol inhibits the reaction [Paclitaxel results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:12510025 PMID:18516295 |
|
NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
|
|
G |
Ramp1 |
receptor activity modifying protein 1 |
multiple interactions |
ISO |
RAMP1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 9:98,313,632...98,364,206
Ensembl chr 9:98,313,632...98,364,205
|
|
G |
Rapgef5 |
Rap guanine nucleotide exchange factor 5 |
increases expression |
ISO |
Paclitaxel results in increased expression of RAPGEF5 protein |
CTD |
PMID:15907983 |
|
NCBI chr 6:145,387,890...145,625,243
Ensembl chr 6:145,546,595...145,625,236
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions increases expression |
EXP |
Tretinoin promotes the reaction [Paclitaxel results in increased expression of RARB mRNA] |
CTD |
PMID:21865574 |
|
NCBI chr15:9,915,223...10,262,599
Ensembl chr15:10,120,206...10,262,599
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions increases phosphorylation |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased phosphorylation of RB1 protein] |
CTD |
PMID:15138593 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rbbp9 |
RB binding protein 9, serine hydrolase |
decreases expression |
ISO |
Paclitaxel results in decreased expression of RBBP9 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr 3:138,701,579...138,708,332
Ensembl chr 3:138,701,586...138,708,332
|
|
G |
Rbp1 |
retinol binding protein 1 |
increases response to substance |
ISO |
RBP1 protein results in increased susceptibility to Paclitaxel |
CTD |
PMID:16734730 |
|
NCBI chr 8:106,449,321...106,470,842
Ensembl chr 8:106,449,321...106,470,842
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression increases phosphorylation multiple interactions |
ISO EXP |
Paclitaxel results in decreased expression of RELA protein Paclitaxel results in increased phosphorylation of RELA protein 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl)piperidine inhibits the reaction [Paclitaxel results in increased phosphorylation of RELA protein]; Paclitaxel promotes the reaction [RELA protein binds to IRF8 promoter] ITGAM protein affects the reaction [Paclitaxel affects the localization of and results in increased activity of [NFKB1 protein binds to RELA protein]]; Paclitaxel affects the localization of and results in increased activity of [NFKB1 protein binds to RELA protein] [gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] affects the localization of RELA protein; [gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] results in increased expression of RELA protein; [Paclitaxel co-treated with F2 protein] affects the localization of RELA protein; [Paclitaxel co-treated with Metformin] results in decreased expression of RELA mRNA; [Tretinoin co-treated with Paclitaxel] results in decreased expression of RELA protein; caffeic acid phenethyl ester inhibits the reaction [Paclitaxel results in increased activity of RELA protein]; Curcumin inhibits the reaction [Paclitaxel results in increased activity of RELA protein] |
CTD |
PMID:11123339 PMID:15291876 PMID:16243823 PMID:17039268 PMID:17701358 PMID:18098270 PMID:19944065 PMID:29309887 PMID:30414958 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rfc5 |
replication factor C subunit 5 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of RFC5 protein |
CTD |
PMID:15907983 |
|
NCBI chr12:44,931,494...44,941,051
Ensembl chr12:44,931,494...44,941,324
|
|
G |
Rfx5 |
regulatory factor X5 |
decreases response to substance |
ISO |
RFX5 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr 2:196,119,054...196,128,109
Ensembl chr 2:196,120,580...196,128,095
|
|
G |
Rfxank |
regulatory factor X-associated ankyrin-containing protein |
affects response to substance |
ISO |
RFXANK protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr16:21,029,449...21,037,080
Ensembl chr16:21,029,596...21,037,078
|
|
G |
Rhot2 |
ras homolog family member T2 |
affects response to substance |
ISO |
RHOT2 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr10:15,205,943...15,211,739
Ensembl chr10:15,205,534...15,211,325
|
|
G |
Ripk2 |
receptor-interacting serine-threonine kinase 2 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of RIPK2 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr 5:29,838,713...29,870,390
Ensembl chr 5:29,838,747...29,870,735
|
|
G |
Rnf19a |
ring finger protein 19A, RBR E3 ubiquitin protein ligase |
decreases expression |
ISO |
Paclitaxel results in decreased expression of RNF19A mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 7:75,058,758...75,098,331
Ensembl chr 7:75,058,758...75,098,331
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
increases expression |
ISO |
Paclitaxel results in increased expression of ROCK1 mRNA |
CTD |
PMID:15000894 |
|
NCBI chr18:1,273,490...1,390,790
Ensembl chr18:1,273,453...1,390,190
|
|
G |
Rpl10 |
ribosomal protein L10 |
affects response to substance |
ISO |
RPL10 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr X:156,438,251...156,440,461
Ensembl chr X:156,438,251...156,440,461
|
|
G |
Rpl22l1 |
ribosomal protein L22 like 1 |
decreases expression |
ISO |
Paclitaxel results in decreased expression of RPL22L1 mRNA |
CTD |
PMID:12929121 |
|
NCBI chr 2:115,362,799...115,364,735
Ensembl chr 2:115,362,799...115,364,729
|
|
G |
Rpl23a |
ribosomal protein L23a |
decreases response to substance |
ISO |
RPL23A mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr10:65,441,295...65,443,981
Ensembl chr10:65,441,295...65,443,981
|
|
G |
Rplp1 |
ribosomal protein lateral stalk subunit P1 |
decreases response to substance |
ISO |
RPLP1 mRNA results in decreased susceptibility to Paclitaxel |
CTD |
PMID:16322897 |
|
NCBI chr 8:66,862,143...66,863,476
Ensembl chr 8:66,862,143...66,863,476
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[Paclitaxel co-treated with Metformin] results in decreased expression of RPS6KB1 mRNA |
CTD |
PMID:29309887 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions |
ISO |
RRM2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 6:43,884,627...43,890,818
Ensembl chr 6:43,884,678...43,889,515
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
Paclitaxel results in increased expression of RRM2B mRNA |
CTD |
PMID:21704725 |
|
NCBI chr 7:76,750,045...76,780,817
Ensembl chr 7:76,750,050...76,780,817
|
|
G |
Rs1 |
retinoschisin 1 |
decreases secretion |
ISO |
Paclitaxel results in decreased secretion of RS1 protein |
CTD |
PMID:21738583 |
|
NCBI chr X:35,749,957...35,777,243
Ensembl chr X:35,749,957...35,777,243
|
|
G |
Rsrp1 |
arginine and serine rich protein 1 |
affects response to substance |
ISO |
RSRP1 protein affects the susceptibility to Paclitaxel |
CTD |
PMID:16217747 |
|
NCBI chr 5:153,260,930...153,264,669
Ensembl chr 5:153,260,930...153,264,669
|
|
G |
RT1-EC2 |
RT1 class Ib, locus EC2 |
increases expression |
EXP |
Paclitaxel results in increased expression of RT1-EC2 mRNA |
CTD |
PMID:18754875 |
|
|
|
G |
Rtkn |
rhotekin |
multiple interactions decreases response to substance |
|